[Congressional Record Volume 152, Number 134 (Thursday, December 7, 2006)]
[House]
[Pages H8950-H8966]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 2006
Mr. SOUDER. Madam Speaker, I move to suspend the rules and pass the
bill (H.R. 6344) to reauthorize the Office of National Drug Control
Policy Act, as amended.
The Clerk read as follows:
H.R. 6344
Be it enacted by the Senate and House of Representatives of
the United States of America in Congress assembled,
SECTION 1. SHORT TITLE, REFERENCE, AND TABLE OF CONTENTS.
(a) Short Title.--This Act may be cited as the ``Office of
National Drug Control Policy Reauthorization Act of 2006''.
(b) Amendment of Office of National Drug Control Policy
Reauthorization Act of 1998.--Except as otherwise expressly
provided, whenever in this Act an amendment or repeal is
expressed in terms of an amendment to, or repeal of, a
section or other provision, the reference shall be considered
to be made to a section or other provision of the Office of
National Drug Control Policy Reauthorization Act of 1998
(Public Law 105-277; 21 U.S.C. 1701 et seq.).
(c) Table of Contents.--The table of contents for this Act
is as follows:
Sec. 1. Short title, reference, and table of contents.
TITLE I--ORGANIZATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY AND
ROLES AND RESPONSIBILITIES
Sec. 101. Amendments to definitions.
Sec. 102. Establishment of the Office of National Drug Control Policy.
Sec. 103. Appointment and responsibilities of the Director.
Sec. 104. Amendments to ensure coordination with other agencies.
Sec. 105. Budgetary matters.
TITLE II--THE NATIONAL DRUG CONTROL STRATEGY
Sec. 201. Annual preparation and submission of National Drug Control
Strategy.
Sec. 202. Performance measurements.
Sec. 203. Annual report requirement.
TITLE III--HIGH INTENSITY DRUG TRAFFICKING AREAS
Sec. 301. High Intensity Drug Trafficking Areas Program.
Sec. 302. Funding for certain high intensity drug trafficking areas.
Sec. 303. Assessment.
TITLE IV--TECHNOLOGY
Sec. 401. Counterdrug Technology Assessment Center.
TITLE V--NATIONAL YOUTH MEDIA CAMPAIGN
Sec. 501. National Youth Anti-Drug Media Campaign.
TITLE VI--AUTHORIZATIONS AND EXTENSION OF TERMINATION DATE
Sec. 601. Authorization of appropriations.
Sec. 602. Extension of termination date.
TITLE VII--ANTI-DOPING AGENCY
Sec. 701. Designation of United States Anti-Doping Agency.
Sec. 702. Records, audit, and report.
Sec. 703. Authorization of appropriations.
TITLE VIII--DRUG-FREE COMMUNITIES
Sec. 801. Reauthorization.
Sec. 802. Suspension of grants.
Sec. 803. Grant award increase.
Sec. 804. Prohibition on additional eligibility criteria.
Sec. 805. National Community Anti-Drug Coalition Institute.
TITLE IX--NATIONAL GUARD COUNTERDRUG SCHOOLS
Sec. 901. National Guard counterdrug schools.
TITLE X--NATIONAL METHAMPHETAMINE INFORMATION CLEARINGHOUSE ACT OF 2006
Sec. 1001. Short title.
Sec. 1002. Definitions.
Sec. 1003. Establishment of clearinghouse and advisory council.
Sec. 1004. NMIC requirements and review.
Sec. 1005. Authorization of appropriations.
TITLE XI--MISCELLANEOUS PROVISIONS
Sec. 1101. Repeals.
Sec. 1102. Controlled Substances Act amendments.
Sec. 1103. Report on law enforcement intelligence sharing.
Sec. 1104. Requirement for South American heroin strategy.
Sec. 1105. Model acts.
Sec. 1106. Study on iatrogenic addiction associated with prescription
opioid analgesic drugs.
[[Page H8951]]
Sec. 1107. Requirement for strategy to stop Internet advertising of
prescription medicines without a prescription.
Sec. 1108. Requirement for study on diversion and inappropriate uses of
prescription drugs.
Sec. 1109. Requirement for Afghan Heroin Strategy.
Sec. 1110. Requirement for Southwest Border Counternarcotics Strategy.
Sec. 1111. Requirement for Scientific Study of Mycoherbicide in Illicit
Drug Crop Eradication.
Sec. 1112. Requirement for Study of State Precursor Chemical Control
Laws.
Sec. 1113. Requirement for Study of Drug Endangered Children Programs.
Sec. 1114. Study on drug court hearings in nontraditional places.
Sec. 1115. Report on tribal Government participation in HIDTA process.
Sec. 1116. Report on school drug testing.
Sec. 1117. Report on ONDCP performance bonuses.
Sec. 1118. Requirement for disclosure of Federal sponsorship of all
Federal advertising or other communication materials.
Sec. 1119. Awards for demonstration programs by local partnerships to
coerce abstinence in chronic hard-drug users under
community supervision through the use of drug testing and
sanctions.
Sec. 1120. Policy relating to syringe exchange programs.
TITLE I--ORGANIZATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY AND
ROLES AND RESPONSIBILITIES
SEC. 101. AMENDMENTS TO DEFINITIONS.
(a) Demand Reduction.--Section 702(1) is amended--
(1) in subparagraph (F), by striking ``and'' after the
semicolon;
(2) in paragraph (G), by striking the period at the end and
inserting ``, including the testing of employees;''; and
(3) by adding at the end the following:
``(H) interventions for drug abuse and dependence;
``(I) international drug control coordination and
cooperation with respect to activities described in this
paragraph; and
``(J) international drug abuse education, prevention,
treatment, research, rehabilitation activities, and
interventions for drug abuse and dependence.''.
(b) National Drug Control Program.--Section 702(6) is
amended by adding before the period the following: ``,
including any activities involving supply reduction, demand
reduction, or State, local, and tribal affairs''.
(c) Program Change.--Section 702(7) is amended by--
(1) striking ``National Foreign Intelligence Program,'' and
inserting ``National Intelligence Program,''; and
(2) inserting after ``Related Activities,'' the following:
``or (for purposes of section 704(d)) an agency that is
described in section 530C(a) of title 28, United States
Code,''.
(d) Office.--Section 702(9) is amended by striking
``implicates'' and inserting ``indicates''.
(e) State, Local, and Tribal Affairs.--Paragraph (10) of
section 702 is amended to read as follows:
``(10) State, local, and tribal affairs.--The term `State,
local, and tribal affairs' means domestic activities
conducted by a National Drug Control Program agency that are
intended to reduce the availability and use of illegal drugs,
including--
``(A) coordination and enhancement of Federal, State,
local, and tribal law enforcement drug control efforts;
``(B) coordination and enhancement of efforts among
National Drug Control Program agencies and State, local, and
tribal demand reduction and supply reduction agencies;
``(C) coordination and enhancement of Federal, State,
local, and tribal law enforcement initiatives to gather,
analyze, and disseminate information and law enforcement
intelligence relating to drug control among domestic law
enforcement agencies; and
``(D) other coordinated and joint initiatives among
Federal, State, local, and tribal agencies to promote
comprehensive drug control strategies designed to reduce the
demand for, and the availability of, illegal drugs.''.
(f) Supply Reduction.--Section 702(11) is amended to read
as follows:
``(11) Supply reduction.--The term `supply reduction' means
any activity or program conducted by a National Drug Control
Program agency that is intended to reduce the availability or
use of illegal drugs in the United States or abroad,
including--
``(A) law enforcement outside the United States;
``(B) source country programs, including economic
development programs primarily intended to reduce the
production or trafficking of illicit drugs;
``(C) activities to control international trafficking in,
and availability of, illegal drugs, including--
``(i) accurate assessment and monitoring of international
drug production and interdiction programs and policies; and
``(ii) coordination and promotion of compliance with
international treaties relating to the production,
transportation, or interdiction of illegal drugs;
``(D) activities to conduct and promote international law
enforcement programs and policies to reduce the supply of
drugs; and
``(E) activities to facilitate and enhance the sharing of
domestic and foreign intelligence information among National
Drug Control Program agencies, relating to the production and
trafficking of drugs in the United States and in foreign
countries.''.
(g) Definitions of Appropriate Congressional Committees and
Law Enforcement.--Section 702 is amended by adding at the end
the following:
``(12) Appropriate congressional committees.--Except where
otherwise provided, the term `appropriate congressional
committees' means the Committee on the Judiciary, the
Committee on Appropriations, and the Caucus on International
Narcotics Control of the Senate and the Committee on
Government Reform, the Committee on the Judiciary, and the
Committee on Appropriations of the House of Representatives.
``(13) Law enforcement.--The term `law enforcement' or
`drug law enforcement' means all efforts by a Federal, State,
local, or tribal government agency to enforce the drug laws
of the United States or any State, including investigation,
arrest, prosecution, and incarceration or other punishments
or penalties.''.
SEC. 102. ESTABLISHMENT OF THE OFFICE OF NATIONAL DRUG
CONTROL POLICY.
(a) Responsibilities.--Section 703(a) is amended to read as
follows:
``(a) Establishment of Office.--There is established in the
Executive Office of the President an Office of National Drug
Control Policy, which shall--
``(1) develop national drug control policy;
``(2) coordinate and oversee the implementation of the
national drug control policy;
``(3) assess and certify the adequacy of National Drug
Control Programs and the budget for those programs; and
``(4) evaluate the effectiveness of the national drug
control policy and the National Drug Control Program
agencies' programs, by developing and applying specific goals
and performance measurements.''.
(b) Positions.--Section 703(b) is amended to read as
follows:
``(b) Director of National Drug Control Policy and Deputy
Directors.--
``(1) Director.--There shall be a Director of National Drug
Control Policy who shall head the Office (referred to in this
Act as the `Director') and shall hold the same rank and
status as the head of an executive department listed in
section 101 of title 5, United States Code.
``(2) Deputy director.--There shall be a Deputy Director of
National Drug Control Policy who shall report directly to the
Director (referred to in this Act as the `Deputy Director').
``(3) Other deputy directors.--
``(A) In general.--There shall be a Deputy Director for
Demand Reduction, a Deputy Director for Supply Reduction, and
a Deputy Director for State, Local, and Tribal Affairs.
``(B) Reporting.--The Deputy Director for Demand Reduction,
the Deputy Director for Supply Reduction, and the Deputy
Director for State, Local, and Tribal Affairs shall report
directly to the Deputy Director of the Office of National
Drug Control Policy.
``(C) Deputy director for demand reduction.--The Deputy
Director for Demand Reduction shall be responsible for the
activities in subparagraphs (A) through (H) of section
702(l).
``(D) Deputy director for supply reduction.--The Deputy
Director for Supply Reduction shall--
``(i) have substantial experience and expertise in drug
interdiction and other supply reduction activities; and
``(ii) be responsible for the activities in subparagraphs
(A) through (C) in section 702(11).
``(E) Deputy director for state, local, and tribal
affairs.--The Deputy Director for State, Local, and Tribal
Affairs shall be responsible for the activities--
``(i) in subparagraphs (A) through (D) of section 702(10);
``(ii) in section 707, the High Intensity Drug Trafficking
Areas Program; and
``(iii) in section 708, the Counterdrug Technology
Assessment Center.''.
SEC. 103. APPOINTMENT AND RESPONSIBILITIES OF THE DIRECTOR.
(a) Succession.--Section 704(a) is amended by amending
paragraph (3) to read as follows:
``(3) Acting director.--If the Director dies, resigns, or
is otherwise unable to perform the functions and duties of
the office, the Deputy Director shall perform the functions
and duties of the Director temporarily in an acting capacity
pursuant to subchapter III of chapter 33 of title 5, United
States Code.''.
(b) Responsibilities.--Section 704(b) is amended--
(1) in paragraph (4), by striking ``Federal departments and
agencies engaged in drug enforcement'' and inserting
``National Drug Control Program agencies'';
(2) in paragraph (7), by inserting after ``President'' the
following: ``and the appropriate congressional committees'';
(3) in paragraph (13), by striking ``(beginning in 1999)'';
(4) by striking paragraph (14) and inserting the following:
``(14) shall submit to the appropriate congressional
committees on an annual basis, not later than 60 days after
the date of the last day of the applicable period, a summary
of--
``(A) each of the evaluations received by the Director
under paragraph (13); and
``(B) the progress of each National Drug Control Program
agency toward the drug control program goals of the agency
using
[[Page H8952]]
the performance measures for the agency developed under
section 706(c);'';
(5) in paragraph (15), by striking subparagraph (C) and
inserting the following:
``(C) supporting the substance abuse information
clearinghouse administered by the Administrator of the
Substance Abuse and Mental Health Services Administration and
established in section 501(d)(16) of the Public Health
Service Act by--
``(i) encouraging all National Drug Control Program
agencies to provide all appropriate and relevant information;
and
``(ii) supporting the dissemination of information to all
interested entities;''; and
(6) by inserting at the end the following:
``(16) shall coordinate with the private sector to promote
private research and development of medications to treat
addiction;
``(17) shall seek the support and commitment of State,
local, and tribal officials in the formulation and
implementation of the National Drug Control Strategy;
``(18) shall monitor and evaluate the allocation of
resources among Federal law enforcement agencies in response
to significant local and regional drug trafficking and
production threats;
``(19) shall submit an annual report to Congress detailing
how the Office of National Drug Control Policy has consulted
with and assisted State, local, and tribal governments with
respect to the formulation and implementation of the National
Drug Control Strategy and other relevant issues; and
``(20) shall, within 1 year after the date of the enactment
of the Office of National Drug Control Policy Reauthorization
Act of 2006, report to Congress on the impact of each Federal
drug reduction strategy upon the availability, addiction
rate, use rate, and other harms of illegal drugs.''.
(c) Review and Certification of National Drug Control
Program Budget.--Section 704(c)(3) is amended--
(1) in subparagraph (C)(iii), by inserting ``and the
appropriate congressional committees,'' after ``House of
Representatives''; and
(2) in subparagraph (D)(ii)(II)(bb), by inserting ``and the
appropriate congressional committees,'' after ``House of
Representatives''.
(d) Powers of Director.--Section 704(d) is amended--
(1) in paragraph (9), by striking ``Strategy; and'' and
inserting ``Strategy and notify the appropriate congressional
committees of any fund control notice issued in accordance
with section 704(f)(5);''; and
(2) in paragraph (10), by inserting before the period the
following: ``and section 706 of the Department of State
Authorization Act for Fiscal Year 2003 (22 U.S.C. 229j-1)''.
(e) Fund Control Notices.--Section 704(f) is amended by
adding at the end the following:
``(4) Congressional notice.--A copy of each fund control
notice shall be transmitted to the appropriate congressional
committees.
``(5) Restrictions.--The Director shall not issue a fund
control notice to direct that all or part of an amount
appropriated to the National Drug Control Program agency
account be obligated, modified, or altered in any manner--
``(A) contrary, in whole or in part, to a specific
appropriation; or
``(B) contrary, in whole or in part, to the expressed
intent of Congress.''.
(f) Drug Interdiction.--
(1) In general.--Section 711 is amended by adding at the
end the following:
``SEC. 711. DRUG INTERDICTION COORDINATOR AND COMMITTEE.
``(a) United States Interdiction Coordinator.--
``(1) In general.--The United States Interdiction
Coordinator shall perform the duties of that position
described in paragraph (2) and such other duties as may be
determined by the Director with respect to coordination of
efforts to interdict illicit drugs from entering the United
States.
``(2) Responsibilities.--The United States Interdiction
Coordinator shall be responsible to the Director for--
``(A) coordinating the interdiction activities of the
National Drug Control Program agencies to ensure consistency
with the National Drug Control Strategy;
``(B) on behalf of the Director, developing and issuing, on
or before March 1 of each year and in accordance with
paragraph (3), a National Interdiction Command and Control
Plan to ensure the coordination and consistency described in
subparagraph (A);
``(C) assessing the sufficiency of assets committed to
illicit drug interdiction by the relevant National Drug
Control Program agencies; and
``(D) advising the Director on the efforts of each National
Drug Control Program agency to implement the National
Interdiction Command and Control Plan.
``(3) Staff.--The Director shall assign such permanent
staff of the Office as he considers appropriate to assist the
United States Interdiction Coordinator to carry out the
responsibilities described in paragraph (2), and may also, at
his discretion, request that appropriate National Drug
Control Program agencies detail or assign staff to the Office
of Supply Reduction for that purpose.
``(4) National interdiction command and control plan.--
``(A) Purposes.--The National Interdiction Command and
Control Plan shall--
``(i) set forth the Government's strategy for drug
interdiction;
``(ii) state the specific roles and responsibilities of the
relevant National Drug Control Program agencies for
implementing that strategy; and
``(iii) identify the specific resources required to enable
the relevant National Drug Control Program agencies to
implement that strategy.
``(B) Consultation with other agencies.--The United States
Interdiction Coordinator shall issue the National
Interdiction Command and Control Plan in consultation with
the other members of the Interdiction Committee described in
subsection (b).
``(C) Limitation.--The National Interdiction Command and
Control Plan shall not change existing agency authorities or
the laws governing interagency relationships, but may include
recommendations about changes to such authorities or laws.
``(D) Report to congress.--On or before March 1 of each
year, the United States Interdiction Coordinator shall
provide a report on behalf of the Director to the appropriate
congressional committees, to the Committee on Armed Services
and the Committee on Homeland Security of the House of
Representatives, and to the Committee on Homeland Security
and Governmental Affairs and the Committee on Armed Services
of the Senate, which shall include--
``(i) a copy of that year's National Interdiction Command
and Control Plan;
``(ii) information for the previous 10 years regarding the
number and type of seizures of drugs by each National Drug
Control Program agency conducting drug interdiction
activities, as well as statistical information on the
geographic areas of such seizures; and
``(iii) information for the previous 10 years regarding the
number of air and maritime patrol hours undertaken by each
National Drug Control Program agency conducting drug
interdiction activities, as well as statistical information
on the geographic areas in which such patrol hours took
place.
``(E) Treatment of classified or law enforcement sensitive
information.--Any content of the report described in
subparagraph (D) that involves information classified under
criteria established by an Executive order, or the public
disclosure of which, as determined by the Director, the
Director of National Intelligence, or the head of any Federal
Government agency the activities of which are described in
the plan, would be detrimental to the law enforcement or
national security activities of any Federal, State, or local
agency, shall be presented to Congress separately from the
rest of the report.
``(b) Interdiction Committee.--
``(1) In general.--The Interdiction Committee shall meet
to--
``(A) discuss and resolve issues related to the
coordination, oversight and integration of international,
border, and domestic drug interdiction efforts in support of
the National Drug Control Strategy;
``(B) review the annual National Interdiction Command and
Control Plan, and provide advice to the Director and the
United States Interdiction Coordinator concerning that plan;
and
``(C) provide such other advice to the Director concerning
drug interdiction strategy and policies as the committee
determines is appropriate.
``(2) Chairman.--The Director shall designate one of the
members of the Interdiction Committee to serve as chairman.
``(3) Meetings.--The members of the Interdiction Committee
shall meet, in person and not through any delegate or
representative, at least once per calendar year, prior to
March 1. At the call of either the Director or the current
chairman, the Interdiction Committee may hold additional
meetings, which shall be attended by the members either in
person, or through such delegates or representatives as they
may choose.
``(4) Report.--Not later than September 30 of each year,
the chairman of the Interdiction Committee shall submit a
report to the Director and to the appropriate congressional
committees describing the results of the meetings and any
significant findings of the Committee during the previous 12
months. Any content of such a report that involves
information classified under criteria established by an
Executive order, or whose public disclosure, as determined by
the Director, the chairman, or any member, would be
detrimental to the law enforcement or national security
activities of any Federal, State, local, or tribal agency,
shall be presented to Congress separately from the rest of
the report. by striking subsection (d) and redesignating
subsections (e), (f), and (g) as subsections (d), (e), and
(f), respectively.''.
(2) Conforming amendment to homeland security act of
2002.--Section 878 of the Homeland Security Act of 2002 (6
U.S.C. 458) is amended--
(A) in subsection (c), by striking ``Except as provided in
subsection (d), the'' and inserting ``The''; and
(B) by striking subsection (d) and redesignating
subsections (e), (f), and (g) as subsections (d), (e), and
(f), respectively.
(3) Technical amendments.--Section 704 (21 U.S.C. 1703) is
amended--
(A) by amending subsection (g) to read as follows:
``(g) Inapplicability to Certain Programs.--The provisions
of this section shall not apply to the National Intelligence
Program, the Joint Military Intelligence Program, and
Tactical and Related Activities, unless such program or an
element of such program is designated as a National Drug
Control Program--
[[Page H8953]]
``(1) by the President; or
``(2) jointly by--
``(A) in the case of the National Intelligence Program, the
Director and the Director of National Intelligence; or
``(B) in the case of the Joint Military Intelligence
Program and Tactical and Related Activities, the Director,
the Director of National Intelligence, and the Secretary of
Defense.''; and
(B) by amending subsection (h) to read as follows:
``(h) Construction.--Nothing in this Act shall be construed
as derogating the authorities and responsibilities of the
Director of National Intelligence or the Director of the
Central Intelligence Agency contained in the National
Security Act of 1947 (50 U.S.C. 401 et seq.), the Central
Intelligence Agency Act of 1949 (50 U.S.C. 403a et seq.), or
any other law.''.
SEC. 104. AMENDMENTS TO ENSURE COORDINATION WITH OTHER
AGENCIES.
Section 705 is amended--
(1) in subsection (a)(1)(A), by striking ``abuse'';
(2) in subsection (a)(2)(A), by striking ``Director of
Central Intelligence'' and inserting ``Director of National
Intelligence'';
(3) in subsection (a)(2)(B), by striking ``Director of
Central Intelligence'' and inserting ``Director of National
Intelligence and the Director of the Central Intelligence
Agency'';
(4) by amending subsection (a)(3) to read as follows:
``(3) Required reports.--
``(A) Secretaries of the interior and agriculture.--Not
later than July 1 of each year, the Secretaries of
Agriculture and the Interior shall jointly submit to the
Director and the appropriate congressional committees an
assessment of the quantity of illegal drug cultivation and
manufacturing in the United States on lands owned or under
the jurisdiction of the Federal Government for the preceding
year.
``(B) Secretary of homeland security.--Not later than July
1 of each year, the Secretary of Homeland Security shall
submit to the Director and the appropriate congressional
committees information for the preceding year regarding--
``(i) the number and type of seizures of drugs by each
component of the Department of Homeland Security seizing
drugs, as well as statistical information on the geographic
areas of such seizures; and
``(ii) the number of air and maritime patrol hours
primarily dedicated to drug supply reduction missions
undertaken by each component of the Department of Homeland
Security.
``(C) Secretary of defense.--The Secretary of Defense
shall, by July 1 of each year, submit to the Director and the
appropriate congressional committees information for the
preceding year regarding the number of air and maritime
patrol hours primarily dedicated to drug supply reduction
missions undertaken by each component of the Department of
Defense.
``(D) Attorney general.--The Attorney General shall, by
July 1 of each year, submit to the Director and the
appropriate congressional committees information for the
preceding year regarding the number and type of--
``(i) arrests for drug violations;
``(ii) prosecutions for drug violations by United States
Attorneys; and
``(iii) seizures of drugs by each component of the
Department of Justice seizing drugs, as well as statistical
information on the geographic areas of such seizures.'';
(5) in subsection (b)(2)(B), by striking ``Program'' and
inserting ``Strategy''; and
(6) in subsection (c), by striking ``in'' and inserting
``on''.
SEC. 105. BUDGETARY MATTERS.
(a) Submission of Drug Control Budget Requests.--Section
704(c)(1) is amended by adding at the end the following:
``(C) Content of drug control budget requests.--A drug
control budget request submitted by a department, agency, or
program under this paragraph shall include all requests for
funds for any drug control activity undertaken by that
department, agency, or program, including demand reduction,
supply reduction, and State, local, and tribal affairs,
including any drug law enforcement activities. If an activity
has both drug control and nondrug control purposes or
applications, the department, agency, or program shall
estimate by a documented calculation the total funds
requested for that activity that would be used for drug
control, and shall set forth in its request the basis and
method for making the estimate.''.
(b) National Drug Control Budget Proposal.--
(1) National organizations.--Section 704(c)(2) is amended
by inserting ``and the head of each major national
organization that represents law enforcement officers,
agencies, or associations'' after ``agency''.
(2) Total budget.--Section 704(c)(2)(A) is amended by
inserting before the semicolon: ``and to inform Congress and
the public about the total amount proposed to be spent on all
supply reduction, demand reduction, State, local, and tribal
affairs, including any drug law enforcement, and other drug
control activities by the Federal Government, which shall
conform to the content requirements set forth in paragraph
(1)(C)''.
(c) Review and Certification of National Drug Control
Program Budget.--Section 704(c)(3) is amended--
(1) by redesignating subparagraphs (C) and (D) as
subparagraphs (D) and (E), respectively;
(2) by inserting after subparagraph (B) the following new
subparagraph:
``(C) Specific requests.--The Director shall not confirm
the adequacy of any budget request that--
``(i) requests funding for Federal law enforcement
activities that do not adequately compensate for transfers of
drug enforcement resources and personnel to law enforcement
and investigation activities;
``(ii) requests funding for law enforcement activities on
the borders of the United States that do not adequately
direct resources to drug interdiction and enforcement;
``(iii) requests funding for drug treatment activities that
do not provide adequate results and accountability measures;
``(iv) requests funding for any activities of the Safe and
Drug-Free Schools Program that do not include a clear anti-
drug message or purpose intended to reduce drug use;
``(v) requests funding for drug treatment activities that
do not adequately support and enhance Federal drug treatment
programs and capacity;
``(vi) requests funding for fiscal year 2007 for activities
of the Department of Education, unless it is accompanied by a
report setting forth a plan for providing expedited
consideration of student loan applications for all
individuals who submitted an application for any Federal
grant, loan, or work assistance that was rejected or denied
pursuant to 484(r)(1) of the Higher Education Act of 1965 (20
U.S.C. 1091(r)(1)) by reason of a conviction for a drug-
related offense not occurring during a period of enrollment
for which the individual was receiving any Federal grant,
loan, or work assistance; and
``(vii) requests funding for the operations and management
of the Department of Homeland Security that does not include
a specific request for funds for the Office of
Counternarcotics Enforcement to carry out its
responsibilities under section 878 of the Homeland Security
Act of 2002 (6 U.S.C. 458).'';
(3) in subparagraph (D)(iii), as so redesignated, by
inserting ``and the appropriate congressional committees''
after ``House of Representatives''; and
(4) in subparagraph (E)(ii)(II)(bb), as so redesignated, by
inserting ``and the appropriate congressional committees''
after ``House of Representatives''.
(d) Reprogramming and Transfer Requests.--Section
704(c)(4)(A) (21 U.S.C. 1703(c)(4)(A)) is amended--
(1) by striking ``$5,000,000'' and inserting
``$1,000,000''; and
(2) adding at the end the following: ``If the Director has
not responded to a request for reprogramming subject to this
subparagraph within 30 days after receiving notice of the
request having been made, the request shall be deemed
approved by the Director under this subparagraph and
forwarded to Congress.''.
(e) Powers of Director.--Section 704(d) is amended--
(1) in paragraph (8)(D), by striking ``have been authorized
by Congress;'' and inserting ``authorized by law;'';
(2) in paragraph (9), by striking ``Strategy; and'' and
inserting ``Strategy and notify the appropriate congressional
committees of any fund control notice issued; and''; and
(3) in paragraph (10), by striking ``(22 U.S.C. 2291j).''
and inserting ``(22 U.S.C. 2291j) and section 706 of the
Foreign Relations Authorization Act, Fiscal Year 2003 (22
U.S.C. 2291j-1).''.
(f) Fund Control Notices.--Section 704(f) (21 U.S.C.
1703(f)) is amended by adding at the end the following:
``(4) Congressional notice.--A copy of each fund control
notice shall be transmitted to the appropriate congressional
committees.
``(5) Restrictions.--The Director shall not issue a fund
control notice to direct that all or part of an amount
appropriated to the National Drug Control Program agency
account be obligated, modified, or altered in any manner
contrary, in whole or in part, to a specific appropriation or
statute.''.
TITLE II--THE NATIONAL DRUG CONTROL STRATEGY
SEC. 201. ANNUAL PREPARATION AND SUBMISSION OF NATIONAL DRUG
CONTROL STRATEGY.
Section 706 is amended to read as follows:
``SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND
ASSESSMENT OF NATIONAL DRUG CONTROL STRATEGY.
``(a) Timing, Contents, and Process for Development and
Submission of National Drug Control Strategy.--
``(1) Timing.--Not later than February 1 of each year, the
President shall submit to Congress a National Drug Control
Strategy, which shall set forth a comprehensive plan for the
year to reduce illicit drug use and the consequences of such
illicit drug use in the United States by limiting the
availability of, and reducing the demand for, illegal drugs.
``(2) Contents.--
``(A) In general.--The National Drug Control Strategy
submitted under paragraph (1) shall include the following:
``(i) Comprehensive, research-based, long-range,
quantifiable goals for reducing illicit drug use and the
consequences of illicit drug use in the United States.
``(ii) Annual quantifiable and measurable objectives and
specific targets to accomplish long-term quantifiable goals
that the Director determines may be achieved during each
[[Page H8954]]
year beginning on the date on which the National Drug Control
Strategy is submitted.
``(iii) A 5-year projection for program and budget
priorities.
``(iv) A review of international, State, local, and private
sector drug control activities to ensure that the United
States pursues coordinated and effective drug control at all
levels of government.
``(v) An assessment of current illicit drug use (including
inhalants and steroids) and availability, impact of illicit
drug use, and treatment availability, which assessment shall
include--
``(I) estimates of drug prevalence and frequency of use as
measured by national, State, and local surveys of illicit
drug use and by other special studies of nondependent and
dependent illicit drug use;
``(II) illicit drug use in the workplace and the
productivity lost by such use; and
``(III) illicit drug use by arrestees, probationers, and
parolees.
``(vi) An assessment of the reduction of illicit drug
availability, as measured by--
``(I) the quantities of cocaine, heroin, marijuana,
methamphetamine, ecstasy, and other drugs available for
consumption in the United States;
``(II) the amount of marijuana, cocaine, heroin,
methamphetamine, ecstasy, and precursor chemicals and other
drugs entering the United States;
``(III) the number of illicit drug manufacturing
laboratories seized and destroyed and the number of hectares
of marijuana, poppy, and coca cultivated and destroyed
domestically and in other countries;
``(IV) the number of metric tons of marijuana, heroin,
cocaine, and methamphetamine seized and other drugs; and
``(V) changes in the price and purity of heroin,
methamphetamine, and cocaine, changes in the price of
ecstasy, and changes in tetrahydrocannabinol level of
marijuana and other drugs.
``(vii) An assessment of the reduction of the consequences
of illicit drug use and availability, which shall include--
``(I) the burden illicit drug users placed on hospital
emergency departments in the United States, such as the
quantity of illicit drug-related services provided;
``(II) the annual national health care cost of illicit drug
use; and
``(III) the extent of illicit drug-related crime and
criminal activity.
``(viii) A determination of the status of drug treatment in
the United States, by assessing--
``(I) public and private treatment utilization; and
``(II) the number of illicit drug users the Director
estimates meet diagnostic criteria for treatment.
``(ix) A review of the research agenda of the Counterdrug
Technology Assessment Center to reduce the availability and
abuse of drugs.
``(x) A summary of the efforts made to coordinate with
private sector entities to conduct private research and
development of medications to treat addiction by--
``(I) screening chemicals for potential therapeutic value;
``(II) developing promising compounds;
``(III) conducting clinical trials;
``(IV) seeking Food and Drug Administration approval for
drugs to treat addiction;
``(V) marketing the drug for the treatment of addiction;
``(VI) urging physicians to use the drug in the treatment
of addiction; and
``(VII) encouraging insurance companies to reimburse the
cost of the drug for the treatment of addiction.
``(xi) An assessment of Federal effectiveness in achieving
the National Drug Control Strategy for the previous year,
including a specific evaluation of whether the objectives and
targets for reducing illicit drug use for the previous year
were met and reasons for the success or failure of the
previous year's Strategy.
``(xii) A general review of the status of, and trends in,
demand reduction activities by private sector entities and
community-based organizations, including faith-based
organizations, to determine their effectiveness and the
extent of cooperation, coordination, and mutual support
between such entities and organizations and Federal, State,
local, and tribal government agencies.
``(xiii) Such additional statistical data and information
as the Director considers appropriate to demonstrate and
assess trends relating to illicit drug use, the effects and
consequences of illicit drug use (including the effects on
children of substance abusers), supply reduction, demand
reduction, drug-related law enforcement, and the
implementation of the National Drug Control Strategy.
``(xiv) A supplement reviewing the activities of each
individual National Drug Control Program agency during the
previous year with respect to the National Drug Control
Strategy and the Director's assessment of the progress of
each National Drug Control Program agency in meeting its
responsibilities under the National Drug Control Strategy.
``(B) Classified information.--Any contents of the National
Drug Control Strategy that involve information properly
classified under criteria established by an Executive order
shall be presented to Congress separately from the rest of
the National Drug Control Strategy.
``(C) Selection of data and information.--In selecting data
and information for inclusion under subparagraph (A), the
Director shall ensure--
``(i) the inclusion of data and information that will
permit analysis of current trends against previously compiled
data and information where the Director believes such
analysis enhances long-term assessment of the National Drug
Control Strategy; and
``(ii) the inclusion of data and information to permit a
standardized and uniform assessment of the effectiveness of
drug treatment programs in the United States.
``(3) Process for development and submission.--In
developing and effectively implementing the National Drug
Control Strategy, the Director--
``(A) shall consult with--
``(i) the heads of the National Drug Control Program
agencies;
``(ii) Congress;
``(iii) State, local, and tribal officials;
``(iv) private citizens and organizations, including
community and faith-based organizations with experience and
expertise in demand reduction;
``(v) private citizens and organizations with experience
and expertise in supply reduction; and
``(vi) appropriate representatives of foreign governments;
``(B) in satisfying the requirements of subparagraph (A),
shall ensure, to the maximum extent possible, that State,
local, and tribal officials and relevant private
organizations commit to support and take steps to achieve the
goals and objectives of the National Drug Control Strategy;
``(C) with the concurrence of the Attorney General, may
require the El Paso Intelligence Center to undertake specific
tasks or projects to support or implement the National Drug
Control Strategy; and
``(D) with the concurrence of the Director of National
Intelligence and the Attorney General, may request that the
National Drug Intelligence Center undertake specific tasks or
projects to support or implement the National Drug Control
Strategy.
``(b) Submission of Revised Strategy.--The President may
submit to Congress a revised National Drug Control Strategy
that meets the requirements of this section--
``(1) at any time, upon a determination of the President,
in consultation with the Director, that the National Drug
Control Strategy in effect is not sufficiently effective; or
``(2) if a new President or Director takes office.''.
SEC. 202. PERFORMANCE MEASUREMENTS.
Section 706 is amended by adding at the end the following:
``(c) Performance Measurement System.--Not later than
February 1 of each year, the Director shall submit to
Congress as part of the National Drug Control Strategy, a
description of a national drug control performance
measurement system, that--
``(1) develops 2-year and 5-year performance measures and
targets for each National Drug Control Strategy goal and
objective established for reducing drug use, availability,
and the consequences of drug use;
``(2) describes the sources of information and data that
will be used for each performance measure incorporated into
the performance measurement system;
``(3) identifies major programs and activities of the
National Drug Control Program agencies that support the goals
and annual objectives of the National Drug Control Strategy;
``(4) evaluates the contribution of demand reduction and
supply reduction activities as defined in section 702
implemented by each National Drug Control Program agency in
support of the National Drug Control Strategy;
``(5) monitors consistency between the drug-related goals
and objectives of the National Drug Control Program agencies
and ensures that each agency's goals and budgets support and
are fully consistent with the National Drug Control Strategy;
and
``(6) coordinates the development and implementation of
national drug control data collection and reporting systems
to support policy formulation and performance measurement,
including an assessment of--
``(A) the quality of current drug use measurement
instruments and techniques to measure supply reduction and
demand reduction activities;
``(B) the adequacy of the coverage of existing national
drug use measurement instruments and techniques to measure
the illicit drug user population, and groups that are at risk
for illicit drug use;
``(C) the adequacy of the coverage of existing national
treatment outcome monitoring systems to measure the
effectiveness of drug abuse treatment in reducing illicit
drug use and criminal behavior during and after the
completion of substance abuse treatment; and
``(D) the actions the Director shall take to correct any
deficiencies and limitations identified pursuant to
subparagraphs (A) and (B) of this subsection.
``(d) Modifications.--A description of any modifications
made during the preceding year to the national drug
performance measurement system described in subsection (c)
shall be included in each report submitted under subsection
(b).''.
SEC. 203. ANNUAL REPORT REQUIREMENT.
(a) In General.--On or before February 1 of each year, the
Director shall submit a report to Congress that describes--
(1) the strategy of the national media campaign and whether
specific objectives of the campaign were accomplished;
(2) steps taken to ensure that the national media campaign
operates in an effective and
[[Page H8955]]
efficient manner consistent with the overall strategy and
focus of the campaign;
(3) plans to purchase advertising time and space;
(4) policies and practices implemented to ensure that
Federal funds are used responsibly to purchase advertising
time and space and eliminate the potential for waste, fraud,
and abuse;
(5) all contracts entered into with a corporation,
partnership, or individual working on behalf of the national
media campaign;
(6) specific policies and steps implemented to ensure
compliance with title IV of this Act;
(7) steps taken to ensure that the national media campaign
will secure, to the maximum extent possible, no cost matches
of advertising time and space or in-kind contributions that
are directly related to the campaign in accordance with title
IV of this Act; and
(8) a review and evaluation of the effectiveness of the
national media campaign strategy for the past year.
(b) Audit.--The Government Accountability Office shall, at
a frequency of not less than once per year--
(1) conduct and supervise an audit and investigation
relating to the programs and operations of the--
(A) Office; or
(B) certain programs within the Office, including--
(i) the High Intensity Drug Trafficking Areas Program;
(ii) the Counterdrug Technology Assessment Center; or
(iii) the National Youth Anti-drug Media Campaign; and
(2) provide the Director and the appropriate congressional
committees with a report containing an evaluation of and
recommendations on the--
(A) policies and activities of the programs and operations
subject to the audit and investigation;
(B) economy, efficiency, and effectiveness in the
administration of the reviewed programs and operations; and
(C) policy or management changes needed to prevent and
detect fraud and abuse in such programs and operations.
TITLE III--HIGH INTENSITY DRUG TRAFFICKING AREAS
SEC. 301. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.
Section 707 is amended to read as follows:
``SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.
``(a) Establishment.--
``(1) In general.--There is established in the Office a
program to be known as the High Intensity Drug Trafficking
Areas Program (in this section referred to as the `Program').
``(2) Purpose.--The purpose of the Program is to reduce
drug trafficking and drug production in the United States
by--
``(A) facilitating cooperation among Federal, State, local,
and tribal law enforcement agencies to share information and
implement coordinated enforcement activities;
``(B) enhancing law enforcement intelligence sharing among
Federal, State, local, and tribal law enforcement agencies;
``(C) providing reliable law enforcement intelligence to
law enforcement agencies needed to design effective
enforcement strategies and operations; and
``(D) supporting coordinated law enforcement strategies
which maximize use of available resources to reduce the
supply of illegal drugs in designated areas and in the United
States as a whole.
``(b) Designation.--
``(1) In general.--The Director, in consultation with the
Attorney General, the Secretary of the Treasury, the
Secretary of Homeland Security, heads of the National Drug
Control Program agencies, and the Governor of each applicable
State, may designate any specified area of the United States
as a high intensity drug trafficking area.
``(2) Activities.--After making a designation under
paragraph (1) and in order to provide Federal assistance to
the area so designated, the Director may--
``(A) obligate such sums as are appropriated for the
Program;
``(B) direct the temporary reassignment of Federal
personnel to such area, subject to the approval of the head
of the department or agency that employs such personnel;
``(C) take any other action authorized under section 704 to
provide increased Federal assistance to those areas; and
``(D) coordinate activities under this section
(specifically administrative, recordkeeping, and funds
management activities) with State, local, and tribal
officials.
``(c) Petitions for Designation.--The Director shall
establish regulations under which a coalition of interested
law enforcement agencies from an area may petition for
designation as a high intensity drug trafficking area. Such
regulations shall provide for a regular review by the
Director of the petition, including a recommendation
regarding the merit of the petition to the Director by a
panel of qualified, independent experts.
``(d) Factors for Consideration.--In considering whether to
designate an area under this section as a high intensity drug
trafficking area, the Director shall consider, in addition to
such other criteria as the Director considers to be
appropriate, the extent to which--
``(1) the area is a significant center of illegal drug
production, manufacturing, importation, or distribution;
``(2) State, local, and tribal law enforcement agencies
have committed resources to respond to the drug trafficking
problem in the area, thereby indicating a determination to
respond aggressively to the problem;
``(3) drug-related activities in the area are having a
significant harmful impact in the area, and in other areas of
the country; and
``(4) a significant increase in allocation of Federal
resources is necessary to respond adequately to drug-related
activities in the area.
``(e) Organization of High Intensity Drug Trafficking
Areas.--
``(1) Executive board and officers.--To be eligible for
funds appropriated under this section, each high intensity
drug trafficking area shall be governed by an Executive
Board. The Executive Board shall designate a chairman, vice
chairman, and any other officers to the Executive Board that
it determines are necessary.
``(2) Responsibilities.--The Executive Board of a high
intensity drug trafficking area shall be responsible for--
``(A) providing direction and oversight in establishing and
achieving the goals of the high intensity drug trafficking
area;
``(B) managing the funds of the high intensity drug
trafficking area;
``(C) reviewing and approving all funding proposals
consistent with the overall objective of the high intensity
drug trafficking area; and
``(D) reviewing and approving all reports to the Director
on the activities of the high intensity drug trafficking
area.
``(3) Board representation.--None of the funds appropriated
under this section may be expended for any high intensity
drug trafficking area, or for a partnership or region of a
high intensity drug trafficking area, if the Executive Board
for such area, region, or partnership, does not apportion an
equal number of votes between representatives of
participating Federal agencies and representatives of
participating State, local, and tribal agencies. Where it is
impractical for an equal number of representatives of Federal
agencies and State, local, and tribal agencies to attend a
meeting of an Executive Board in person, the Executive Board
may use a system of proxy votes or weighted votes to achieve
the voting balance required by this paragraph.
``(4) No agency relationship.--The eligibility requirements
of this section are intended to ensure the responsible use of
Federal funds. Nothing in this section is intended to create
an agency relationship between individual high intensity drug
trafficking areas and the Federal Government.
``(f) Use of Funds.--The Director shall ensure that no
Federal funds appropriated for the Program are expended for
the establishment or expansion of drug treatment programs,
and shall ensure that not more than 5 percent of the Federal
funds appropriated for the Program are expended for the
establishment of drug prevention programs.
``(g) Counterterrorism Activities.--
``(1) Assistance authorized.--The Director may authorize
use of resources available for the Program to assist Federal,
State, local, and tribal law enforcement agencies in
investigations and activities related to terrorism and
prevention of terrorism, especially but not exclusively with
respect to such investigations and activities that are also
related to drug trafficking.
``(2) Limitation.--The Director shall ensure--
``(A) that assistance provided under paragraph (1) remains
incidental to the purpose of the Program to reduce drug
availability and carry out drug-related law enforcement
activities; and
``(B) that significant resources of the Program are not
redirected to activities exclusively related to terrorism,
except on a temporary basis under extraordinary
circumstances, as determined by the Director.
``(h) Role of Drug Enforcement Administration.--The
Director, in consultation with the Attorney General, shall
ensure that a representative of the Drug Enforcement
Administration is included in the Intelligence Support Center
for each high intensity drug trafficking area.
``(i) Annual HIDTA Program Budget Submissions.--As part of
the documentation that supports the President's annual budget
request for the Office, the Director shall submit to Congress
a budget justification that includes--
``(1) the amount proposed for each high intensity drug
trafficking area, conditional upon a review by the Office of
the request submitted by the HIDTA and the performance of the
HIDTA, with supporting narrative descriptions and rationale
for each request;
``(2) a detailed justification that explains--
``(A) the reasons for the proposed funding level; how such
funding level was determined based on a current assessment of
the drug trafficking threat in each high intensity drug
trafficking area;
``(B) how such funding will ensure that the goals and
objectives of each such area will be achieved; and
``(C) how such funding supports the National Drug Control
Strategy; and
``(3) the amount of HIDTA funds used to investigate and
prosecute organizations and individuals trafficking in
methamphetamine in the prior calendar year, and a description
of how those funds were used.
``(j) Emerging Threat Response Fund.--
``(1) In general.--Subject to the availability of
appropriations, the Director may
[[Page H8956]]
expend up to 10 percent of the amounts appropriated under
this section on a discretionary basis, to respond to any
emerging drug trafficking threat in an existing high
intensity drug trafficking area, or to establish a new high
intensity drug trafficking area or expand an existing high
intensity drug trafficking area, in accordance with the
criteria established under paragraph (2).
``(2) Consideration of impact.--In allocating funds under
this subsection, the Director shall consider--
``(A) the impact of activities funded on reducing overall
drug traffic in the United States, or minimizing the
probability that an emerging drug trafficking threat will
spread to other areas of the United States; and
``(B) such other criteria as the Director considers
appropriate.
``(k) Evaluation.--
``(1) Initial report.--Not later than 90 days after the
date of the enactment of this section, the Director shall,
after consulting with the Executive Boards of each designated
high intensity drug trafficking area, submit a report to
Congress that describes, for each designated high intensity
drug trafficking area--
``(A) the specific purposes for the high intensity drug
trafficking area;
``(B) the specific long-term and short-term goals and
objectives for the high intensity drug trafficking area;
``(C) the measurements that will be used to evaluate the
performance of the high intensity drug trafficking area in
achieving the long-term and short-term goals; and
``(D) the reporting requirements needed to evaluate the
performance of the high intensity drug trafficking area in
achieving the long-term and short-term goals.
``(2) Evaluation of hidta program as part of national drug
control strategy.--For each designated high intensity drug
trafficking area, the Director shall submit, as part of the
annual National Drug Control Strategy report, a report that--
``(A) describes--
``(i) the specific purposes for the high intensity drug
trafficking area; and
``(ii) the specific long-term and short-term goals and
objectives for the high intensity drug trafficking area; and
``(B) includes an evaluation of the performance of the high
intensity drug trafficking area in accomplishing the specific
long-term and short-term goals and objectives identified
under paragraph (1)(B).
``(l) Assessment of Drug Enforcement Task Forces in High
Intensity Drug Trafficking Areas.--Not later than 1 year
after the date of enactment of this subsection, and as part
of each subsequent annual National Drug Control Strategy
report, the Director shall submit to Congress a report--
``(1) assessing the number and operation of all federally
funded drug enforcement task forces within each high
intensity drug trafficking area; and
``(2) describing--
``(A) each Federal, State, local, and tribal drug
enforcement task force operating in the high intensity drug
trafficking area;
``(B) how such task forces coordinate with each other, with
any high intensity drug trafficking area task force, and with
investigations receiving funds from the Organized Crime and
Drug Enforcement Task Force;
``(C) what steps, if any, each such task force takes to
share information regarding drug trafficking and drug
production with other federally funded drug enforcement task
forces in the high intensity drug trafficking area;
``(D) the role of the high intensity drug trafficking area
in coordinating the sharing of such information among task
forces;
``(E) the nature and extent of cooperation by each Federal,
State, local, and tribal participant in ensuring that such
information is shared among law enforcement agencies and with
the high intensity drug trafficking area;
``(F) the nature and extent to which information sharing
and enforcement activities are coordinated with joint
terrorism task forces in the high intensity drug trafficking
area; and
``(G) any recommendations for measures needed to ensure
that task force resources are utilized efficiently and
effectively to reduce the availability of illegal drugs in
the high intensity drug trafficking areas.
``(m) Assessment of Law Enforcement Intelligence Sharing in
High Intensity Drug Trafficking Areas Program.--Not later
than 180 days after the date of the enactment of this
section, and as part of each subsequent annual National Drug
Control Strategy report, the Director, in consultation with
the Director of National Intelligence, shall submit to
Congress a report--
``(1) evaluating existing and planned law enforcement
intelligence systems supported by each high intensity drug
trafficking area, or utilized by task forces receiving any
funding under the Program, including the extent to which such
systems ensure access and availability of law enforcement
intelligence to Federal, State, local, and tribal law
enforcement agencies within the high intensity drug
trafficking area and outside of it;
``(2) the extent to which Federal, State, local, and tribal
law enforcement agencies participating in each high intensity
drug trafficking area are sharing law enforcement
intelligence information to assess current drug trafficking
threats and design appropriate enforcement strategies; and
``(3) the measures needed to improve effective sharing of
information and law enforcment intelligence regarding drug
trafficking and drug production among Federal, State, local,
and tribal law enforcement participating in a high intensity
drug trafficking area, and between such agencies and similar
agencies outside the high intensity drug trafficking area.
``(n) Coordination of Law Enforcement Intelligence Sharing
With Organized Crime Drug Enforcement Task Force Program.--
The Director, in consultation with the Attorney General,
shall ensure that any drug enforcement intelligence obtained
by the Intelligence Support Center for each high intensity
drug trafficking area is shared, on a timely basis, with the
drug intelligence fusion center operated by the Organized
Crime Drug Enforcement Task Force of the Department of
Justice.
``(o) Use of Funds To Combat Methamphetamine Trafficking.--
``(1) Requirement.--As part of the documentation that
supports the President's annual budget request for the
Office, the Director shall submit to Congress a report
describing the use of HIDTA funds to investigate and
prosecute organizations and individuals trafficking in
methamphetamine in the prior calendar year.
``(2) Contents.--The report shall include--
``(A) the number of methamphetamine manufacturing
facilities discovered through HIDTA-funded initiatives in the
previous fiscal year;
``(B) the amounts of methamphetamine or listed chemicals
(as that term is defined in section 102(33) of the Controlled
Substances Act (21 U.S.C. 802(33)) seized by HIDTA-funded
initiatives in the area during the previous year; and
``(C) law enforcement intelligence and predictive data from
the Drug Enforcement Administration showing patterns and
trends in abuse, trafficking, and transportation in
methamphetamine and listed chemicals.
``(3) Certification.--Before the Director awards any funds
to a high intensity drug trafficking area, the Director shall
certify that the law enforcement entities participating in
that HIDTA are providing laboratory seizure data to the
national clandestine laboratory database at the El Paso
Intelligence Center.
``(p) Authorization of Appropriations.--There is authorized
to be appropriated to the Office of National Drug Control
Policy to carry out this section--
``(1) $240,000,000 for fiscal year 2007;
``(2) $250,000,000 for fiscal year 2008;
``(3) $260,000,000 for fiscal year 2009;
``(4) $270,000,000 for fiscal year 2010; and
``(5) $280,000,000 for each of fiscal year 2011.''.
SEC. 302. FUNDING FOR CERTAIN HIGH INTENSITY DRUG TRAFFICKING
AREAS.
(a) Short Title.--This section may be cited as the ``Dawson
Family Community Protection Act''.
(b) Findings.--Congress finds the following:
(1) In the early morning hours of October 16, 2002, the
home of Carnell and Angela Dawson was firebombed in apparent
retaliation for Mrs. Dawson's notification to police about
persistent drug distribution activity in their East Baltimore
City neighborhood.
(2) The arson claimed the lives of Mr. and Mrs. Dawson and
their 5 young children, aged 9 to 14.
(3) The horrific murder of the Dawson family is a stark
example of domestic narco-terrorism.
(4) In all phases of counternarcotics law enforcement--from
prevention to investigation to prosecution to reentry--the
voluntary cooperation of ordinary citizens is a critical
component.
(5) Voluntary cooperation is difficult for law enforcement
officials to obtain when citizens feel that cooperation
carries the risk of violent retaliation by illegal drug
trafficking organizations and their affiliates.
(6) Public confidence that law enforcement is doing all it
can to make communities safe is a prerequisite for voluntary
cooperation among people who may be subject to intimidation
or reprisal (or both).
(7) Witness protection programs are insufficient on their
own to provide security because many individuals and families
who strive every day to make distressed neighborhoods livable
for their children, other relatives, and neighbors will
resist or refuse offers of relocation by local, State, and
Federal prosecutorial agencies and because, moreover, the
continued presence of strong individuals and families is
critical to preserving and strengthening the social fabric in
such communities.
(8) Where (as in certain sections of Baltimore City)
interstate trafficking of illegal drugs has severe ancillary
local consequences within areas designated as high intensity
drug trafficking areas, it is important that supplementary
High Intensity Drug Trafficking Areas Program funds be
committed to support initiatives aimed at making the affected
communities safe for the residents of those communities and
encouraging their cooperation with tribal, local, State, and
Federal law enforcement efforts to combat illegal drug
trafficking.
(c) Funding for Certain High Intensity Drug Trafficking
Areas.--Section 707, as amended by section 301, is amended by
adding at the end the following:
``(q) Specific Purposes.--
``(1) In general.--The Director shall ensure that, of the
amounts appropriated for a fiscal year for the Program, at
least
[[Page H8957]]
$7,000,000 is used in high intensity drug trafficking areas
with severe neighborhood safety and illegal drug distribution
problems.
``(2) Required uses.--The funds used under paragraph (1)
shall be used--
``(A) to ensure the safety of neighborhoods and the
protection of communities, including the prevention of the
intimidation of potential witnesses of illegal drug
distribution and related activities; and
``(B) to combat illegal drug trafficking through such
methods as the Director considers appropriate, such as
establishing or operating (or both) a toll-free telephone
hotline for use by the public to provide information about
illegal drug-related activities.''.
SEC. 303. ASSESSMENT.
The Director shall assess the ability of the HIDTA Program
to respond to the so-called ``balloon effect'', whereby urban
drug traffickers facing intensive law enforcement efforts
expand and spread their trafficking and distribution into
rural, suburban, and smaller urban areas by conducting a
demonstration project examining the ability of the New York/
New Jersey HIDTA, with its new single colocated Organized
Crime and Drug Enforcement Task Force/High Intensity Drug
Trafficking Area Strike Force and HIDTA Regional Intelligence
Center, to address the movement of drug traffickers into the
more rural, suburban, and smaller areas encompassed by the
counties of Albany, Onondaga, Monroe, and Erie in New York
State and by annexing these counties into the existing New
York/New Jersey HIDTA.
TITLE IV--TECHNOLOGY
SEC. 401. COUNTERDRUG TECHNOLOGY ASSESSMENT CENTER.
(a) Chief Scientist.--Section 708(b) is amended to read as
follows:
``(b) Chief Scientist.--There shall be at the head of the
Center the Chief Scientist, who shall be appointed by the
Director from among individuals qualified and distinguished
in the area of science, medicine, engineering, or
technology.''.
(b) Responsibilities.--
(1) Research and development.--Section 708 is amended by--
(A) redesignating subsection (d) as subsection (e); and
(B) striking subsection (c) and inserting the following:
``(c) Research and Development Responsibilities.--The
Director, acting through the Chief Scientist, shall--
``(1) identify and define the short-, medium-, and long-
term scientific and technological needs of Federal, State,
local, and tribal drug supply reduction agencies, including--
``(A) advanced surveillance, tracking, and radar imaging;
``(B) electronic support measures;
``(C) communications;
``(D) data fusion, advanced computer systems, and
artificial intelligence; and
``(E) chemical, biological, radiological (including neutron
and electron), and other means of detection;
``(2) identify demand reduction basic and applied research
needs and initiatives, in consultation with affected National
Drug Control Program agencies, including--
``(A) improving treatment through neuroscientific advances;
``(B) improving the transfer of biomedical research to the
clinical setting; and
``(C) in consultation with the National Institute of Drug
Abuse and the Substance Abuse and Mental Health Services
Administration, and through interagency agreements or grants,
examining addiction and rehabilitation research and the
application of technology to expanding the effectiveness and
availability of drug treatment;
``(3) make a priority ranking of such needs identified in
paragraphs (1) and (2) according to fiscal and technological
feasibility, as part of a National Counterdrug Research and
Development Program;
``(4) oversee and coordinate counterdrug technology
initiatives with related activities of other Federal civilian
and military departments;
``(5) provide support to the development and implementation
of the national drug control performance measurement system
established under subsection (c) of section 706; and
``(6) pursuant to the authority of the Director of National
Drug Control Policy under section 704, submit requests to
Congress for the reprogramming or transfer of funds
appropriated for counterdrug technology research and
development.
``(d) Limitation on Authority.--The authority granted to
the Director under this section shall not extend to the
awarding of contracts, management of individual projects, or
other operational activities.''.
(2) Assistance and support.--Subsection (e) of section 708,
as redesignated by this section, is amended to read as
follows:
``(e) Assistance and Support to the Office of National Drug
Control Policy.--The Secretary of Defense, the Secretary of
Homeland Security, and the Secretary of Health and Human
Services shall, to the maximum extent practicable, render
assistance and support to the Office and to the Director in
the conduct of counterdrug technology assessment.''.
(3) Technology transfer program.--Section 708 is amended by
adding at the end the following:
``(f) Technology Transfer Program.--
``(1) Program.--The Chief Scientist, with the advice and
counsel of experts from State, local, and tribal law
enforcement agencies, shall be responsible to the Director
for coordination and implementation of a counterdrug
technology transfer program.
``(2) Purpose.--The purpose of the Technology Transfer
Program shall be for the Counterdrug Technology Assessment
Center to transfer technology and associated training
directly to State, local, and tribal law enforcement
agencies.
``(3) Priority of receipts.--Transfers shall be made in
priority order based on--
``(A) the need of potential recipients for such technology;
``(B) the effectiveness of the technology to enhance
current counterdrug activities of potential recipients; and
``(C) the ability and willingness of potential recipients
to evaluate transferred technology.
``(4) Agreement authority.--The Director may enter into an
agreement with the Secretary of Homeland Security to transfer
technology with both counterdrug and homeland security
applications to State, local, and tribal law enforcement
agencies on a reimbursable basis.
``(5) Report.--On or before July 1 of each year, the
Director shall submit a report to the appropriate
congressional committees that addresses the following:
``(A) The number of requests received during the previous
12 months, including the identity of each requesting agency
and the type of technology requested.
``(B) The number of requests fulfilled during the previous
12 months, including the identity of each recipient agency
and the type of technology transferred.
``(C) A summary of the criteria used in making the
determination on what requests were funded and what requests
were not funded, except that such summary shall not include
specific information on any individual requests.
``(D) A general assessment of the future needs of the
program, based on expected changes in threats, expected
technologies, and likely need from potential recipients.
``(E) An assessment of the effectiveness of the
technologies transferred, based in part on the evaluations
provided by the recipients, with a recommendation whether the
technology should continue to be offered through the
program.''.
(c) Assistance From Secretary of Homeland Security.--
Section 708(d) (21 U.S.C. 1707(d)) is amended by inserting
``, the Secretary of Homeland Security,'' after ``The
Secretary of Defense''.
TITLE V--NATIONAL YOUTH MEDIA CAMPAIGN
SEC. 501. NATIONAL YOUTH ANTI-DRUG MEDIA CAMPAIGN.
(a) In General.--Section 709 (21 U.S.C. 1708) is amended to
read as follows:
``SEC. 709. NATIONAL YOUTH ANTI-DRUG MEDIA CAMPAIGN.
``(a) In General.--The Director shall conduct a national
youth anti-drug media campaign (referred to in this subtitle
as the `national media campaign') in accordance with this
section for the purposes of--
``(1) preventing drug abuse among young people in the
United States;
``(2) increasing awareness of adults of the impact of drug
abuse on young people; and
``(3) encouraging parents and other interested adults to
discuss with young people the dangers of illegal drug use.
``(b) Use of Funds.--
``(1) In general.--Amounts made available to carry out this
section for the national media campaign may only be used for
the following:
``(A) The purchase of media time and space, including the
strategic planning for, and accounting of, such purchases.
``(B) Creative and talent costs, consistent with paragraph
(2)(A).
``(C) Advertising production costs.
``(D) Testing and evaluation of advertising.
``(E) Evaluation of the effectiveness of the national media
campaign.
``(F) The negotiated fees for the winning bidder on
requests for proposals issued either by the Office or its
designee to enter into contracts to carry out activities
authorized by this section.
``(G) Partnerships with professional and civic groups,
community-based organizations, including faith-based
organizations, and government organizations related to the
national media campaign.
``(H) Entertainment industry outreach, interactive
outreach, media projects and activities, public information,
news media outreach, and corporate sponsorship and
participation.
``(I) Operational and management expenses.
``(2) Specific requirements.--
``(A) Creative services.--
``(i) In using amounts for creative and talent costs under
paragraph (1)(B), the Director shall use creative services
donated at no cost to the Government (including creative
services provided by the Partnership for a Drug-Free America)
wherever feasible and may only procure creative services for
advertising--
``(I) responding to high-priority or emergent campaign
needs that cannot timely be obtained at no cost; or
``(II) intended to reach a minority, ethnic, or other
special audience that cannot reasonably be obtained at no
cost; or
``(III) the Director determines that the Partnership for a
Drug-Free America is unable to provide, pursuant to
subsection (d)(2)(B).
[[Page H8958]]
``(ii) Subject to the availability of appropriations, no
more than $1,500,000 may be expended under this section each
fiscal year on creative services, except that the Director
may expend up to $2,000,000 in a fiscal year on creative
services to meet urgent needs of the national media campaign
with advance approval from the Committee on Appropriations of
the Senate and of the House of Representatives upon a showing
of the circumstances causing such urgent needs of the
national media campaign.
``(B) Testing and evaluation of advertising.--In using
amounts for testing and evaluation of advertising under
paragraph (1)(D), the Director shall test all advertisements
prior to use in the national media campaign to ensure that
the advertisements are effective and meet industry-accepted
standards. The Director may waive this requirement for
advertisements using no more than 10 percent of the purchase
of advertising time purchased under this section in a fiscal
year and no more than 10 percent of the advertising space
purchased under this section in a fiscal year, if the
advertisements respond to emergent and time-sensitive
campaign needs or the advertisements will not be widely
utilized in the national media campaign.
``(C) Evaluation of effectiveness of media campaign.--In
using amounts for the evaluation of the effectiveness of the
national media campaign under paragraph (1)(E), the Director
shall--
``(i) designate an independent entity to evaluate by April
20 of each year the effectiveness of the national media
campaign based on data from--
``(I) the Monitoring the Future Study published by the
Department of Health and Human Services;
``(II) the Attitude Tracking Study published by the
Partnership for a Drug-Free America;
``(III) the National Household Survey on Drug Abuse; and
``(IV) other relevant studies or publications, as
determined by the Director, including tracking and evaluation
data collected according to marketing and advertising
industry standards; and
``(ii) ensure that the effectiveness of the national media
campaign is evaluated in a manner that enables consideration
of whether the national media campaign has contributed to
reduction of illicit drug use among youth and such other
measures of evaluation as the Director determines are
appropriate.
``(3) Purchase of advertising time and space.--Subject to
the availability of appropriations, for each fiscal year, not
less than 77 percent of the amounts appropriated under this
section shall be used for the purchase of advertising time
and space for the national media campaign, subject to the
following exceptions:
``(A) In any fiscal year for which less than $125,000,000
is appropriated for the national media campaign, not less
than 72 percent of the amounts appropriated under this
section shall be used for the purchase of advertising time
and space for the national media campaign.
``(B) In any fiscal year for which more than $195,000,000
is appropriated under this section, not less than 82 percent
shall be used for advertising production costs and the
purchase of advertising time and space for the national media
campaign.
``(c) Advertising.--In carrying out this section, the
Director shall ensure that sufficient funds are allocated to
meet the stated goals of the national media campaign.
``(d) Division of Responsibilities and Functions Under the
Program.--
``(1) In general.--The Director, in consultation with the
Partnership for a Drug-Free America, shall determine the
overall purposes and strategy of the national media campaign.
``(2) Responsibilities.--
``(A) Director.--The Director shall be responsible for
implementing a focused national media campaign to meet the
purposes set forth in subsection (a), and shall approve--
``(i) the strategy of the national media campaign;
``(ii) all advertising and promotional material used in the
national media campaign; and
``(iii) the plan for the purchase of advertising time and
space for the national media campaign.
``(B) The partnership for a drug-free america.--The
Director shall request that the Partnership for a Drug-Free
America--
``(i) develop and recommend strategies to achieve the goals
of the national media campaign, including addressing national
and local drug threats in specific regions or States, such as
methamphetamine and ecstasy;
``(ii) create all advertising to be used in the national
media campaign, except advertisements that are--
``(I) provided by other nonprofit entities pursuant to
subsection (f);
``(II) intended to respond to high-priority or emergent
campaign needs that cannot timely be obtained at no cost (not
including production costs and talent reuse payments),
provided that any such advertising material is reviewed by
the Partnership for a Drug-Free America;
``(III) intended to reach a minority, ethnic, or other
special audience that cannot be obtained at no cost (not
including production costs and talent reuse payments),
provided that any such advertising material is reviewed by
the Partnership for a Drug-Free America; or
``(IV) any other advertisements that the Director
determines that the Partnership for a Drug-Free America is
unable to provide or if the Director determines that another
entity is more appropriate, subject to the requirements of
subsection (b)(2)(A).
If the Director determines that another entity is more
appropriate under clause (ii)(IV), the Director shall notify
Congress, through the committees of jurisdiction in the House
and Senate, in writing, not less than 30 days prior to
contracting with a party other than the Partnership for a
Drug-Free America.
``(C) Media buying contractor.--The Director shall enter
into a contract with a media buying contractor to plan and
purchase advertising time and space for the national media
campaign. The media buying contractor shall not provide any
other service or material, or conduct any other function or
activity which the Director determines should be provided by
the Partnership for a Drug-Free America.
``(e) Prohibitions.--None of the amounts made available
under subsection (b) may be obligated or expended for any of
the following:
``(1) To supplant current anti-drug community-based
coalitions.
``(2) To supplant pro bono public service time donated by
national and local broadcasting networks for other public
service campaigns.
``(3) For partisan political purposes, or express advocacy
in support of or to defeat any clearly identified candidate,
clearly identified ballot initiative, or clearly identified
legislative or regulatory proposal.
``(4) To fund advertising that features any elected
officials, persons seeking elected office, cabinet level
officials, or other Federal officials employed pursuant to
section 213 of Schedule C of title 5, Code of Federal
Regulations.
``(5) To fund advertising that does not contain a primary
message intended to reduce or prevent illicit drug use.
``(6) To fund advertising containing a primary message
intended to promote support for the media campaign or private
sector contributions to the media campaign.
``(f) Matching Requirement.--
``(1) In general.--Amounts made available under subsection
(b) for media time and space shall be matched by an equal
amount of non-Federal funds for the national media campaign,
or be matched with in-kind contributions of the same value.
``(2) No-cost match advertising direct relationship
requirement.--The Director shall ensure that at least 70
percent of no-cost match advertising provided directly
relates to substance abuse prevention consistent with the
specific purposes of the national media campaign, except that
in any fiscal year in which less than $125,000,000 is
appropriated to the national media campaign, the Director
shall ensure that at least 85 percent of no-cost match
advertising directly relates to substance abuse prevention
consistent with the specific purposes of the national media
campaign.
``(3) No-cost match advertising not directly related.--The
Director shall ensure that no-cost match advertising that
does not directly relate to substance abuse prevention
consistent with the purposes of the national media campaign
includes a clear anti-drug message. Such message is not
required to be the primary message of the match advertising.
``(g) Financial and Performance Accountability.--The
Director shall cause to be performed--
``(1) audits and reviews of costs of the national media
campaign pursuant to section 304C of the Federal Property and
Administrative Services Act of 1949 (41 U.S.C. 254d); and
``(2) an audit to determine whether the costs of the
national media campaign are allowable under section 306 of
such Act (41 U.S.C. 256).
``(h) Report to Congress.--The Director shall submit on an
annual basis a report to Congress that describes--
``(1) the strategy of the national media campaign and
whether specific objectives of the media campaign were
accomplished;
``(2) steps taken to ensure that the national media
campaign operates in an effective and efficient manner
consistent with the overall strategy and focus of the
national media campaign;
``(3) plans to purchase advertising time and space;
``(4) policies and practices implemented to ensure that
Federal funds are used responsibly to purchase advertising
time and space and eliminate the potential for waste, fraud,
and abuse; and
``(5) all contracts entered into with a corporation,
partnership, or individual working on behalf of the national
media campaign.
``(i) Local Target Requirement.--The Director shall, to the
maximum extent feasible, use amounts made available under
this section for media that focuses on, or includes specific
information on, prevention or treatment resources for
consumers within specific local areas.
``(j) Prevention of Marijuana Use.--
``(1) Findings.--The Congress finds the following:
``(A) 60 percent of adolescent admissions for drug
treatment are based on marijuana use.
``(B) Potency levels of contemporary marijuana,
particularly hydroponically grown marijuana, are
significantly higher than in
[[Page H8959]]
the past, rising from under 1 percent of THC in the mid-1970s
to as high as 30 percent today.
``(C) Contemporary research has demonstrated that youths
smoking marijuana early in life may be up to 5 times more
likely to use hard drugs.
``(D) Contemporary research has demonstrated clear
detrimental effects in adolescent educational achievement
resulting from marijuana use.
``(E) Contemporary research has demonstrated clear
detrimental effects in adolescent brain development resulting
from marijuana use.
``(F) An estimated 9,000,000 Americans a year drive while
under the influence of illegal drugs, including marijuana.
``(G) Marijuana smoke contains 50 to 70 percent more of
certain cancer causing chemicals than tobacco smoke.
``(H) Teens who use marijuana are up to 4 times more likely
to have a teen pregnancy than teens who have not.
``(I) Federal law enforcement agencies have identified
clear links suggesting that trade in hydroponic marijuana
facilitates trade by criminal organizations in hard drugs,
including heroin.
``(J) Federal law enforcement agencies have identified
possible links between trade in cannabis products and
financing for terrorist organizations.
``(2) Emphasis on prevention of youth marijuana use.--In
conducting advertising and activities otherwise authorized
under this section, the Director may emphasize prevention of
youth marijuana use.
``(k) Prevention of Methamphetamine Abuse and Other
Emerging Drug Abuse Threats.--
``(1) Requirement to use 10 percent of funds for
methamphetamine abuse prevention.--The Director shall ensure
that, of the amounts appropriated under this section for the
national media campaign for a fiscal year, not less than 10
percent shall be expended solely for the activities described
subsection (b)(1) with respect to advertisements specifically
intended to reduce the use of methamphetamine.
``(2) Authority to use funds for other drug abuse upon
certification that methamphetamine abuse fell during fiscal
year 2007.--With respect to fiscal year 2008 and any fiscal
year thereafter, if the Director certifies in writing to
Congress that domestic methamphetamine laboratory seizures
(as reported to the El Paso Intelligence Center of the Drug
Enforcement Administration) decreased to at least 75 percent
of the 2006 level, or the Director has documented a highly,
statistically significant increase in a specific drug, from a
baseline determined by locally collected data, that can be
defined as a local drug crisis, the Director may apply
paragraph (1)(A) for that fiscal year with respect to
advertisements specifically intended to reduce the use of
such other drugs.
``(l) Authorization of Appropriations.--There is authorized
to be appropriated to the Office to carry out this section,
$195,000,000 for each of fiscal years 2007 and 2008 and
$210,000,000 for each of fiscal years 2009 through 2011.''.
(b) Repeal of Superseded Provisions.--The Drug-Free Media
Campaign Act of 1998 (21 U.S.C. 1801 et seq.) is repealed.
TITLE VI--AUTHORIZATIONS AND EXTENSION OF TERMINATION DATE
SEC. 601. AUTHORIZATION OF APPROPRIATIONS.
Section 714 is amended--
(1) by striking ``title,'' and inserting ``title except
activities otherwise specified,''; and
(2) by striking ``1999 through 2003'' and inserting ``2006
through 2010''.
SEC. 602. EXTENSION OF TERMINATION DATE.
Section 715(a) is amended by striking ``September 30, 2003,
this title and the amendments made by this title'' and
inserting ``September 30, 2010, this title and the amendments
made to this title''.
TITLE VII--ANTI-DOPING AGENCY
SEC. 701. DESIGNATION OF UNITED STATES ANTI-DOPING AGENCY.
(a) Definitions.--In this title:
(1) United states olympic committee.--The term ``United
States Olympic Committee'' means the organization established
by the ``Ted Stevens Olympic and Amateur Sports Act'' (36
U.S.C. 220501 et seq.).
(2) Amateur athletic competition.--The term ``amateur
athletic competition'' means a contest, game, meet, match,
tournament, regatta, or other event in which amateur athletes
compete (36 U.S.C. 220501(b)(2)).
(3) Amateur athlete.--The term ``amateur athlete'' means an
athlete who meets the eligibility standards established by
the national governing body or paralympic sports organization
for the sport in which the athlete competes (36 U.S.C.
22501(b)(1)).
(4) Gene doping.--The term ``gene doping'' means the
nontherapeutic use of cells, genes, genetic elements, or of
the modulation of gene expression, having the capacity to
enhance athletic performance.
(b) In General.--The United States Anti-Doping Agency
shall--
(1) serve as the independent anti-doping organization for
the amateur athletic competitions recognized by the United
States Olympic Committee;
(2) ensure that athletes participating in amateur athletic
activities recognized by the United States Olympic Committee
are prevented from using performance-enhancing drugs, or
performance-enhancing genetic modifications accomplished
through gene-doping;
(3) implement anti-doping education, research, testing, and
adjudication programs to prevent United States Amateur
Athletes participating in any activity recognized by the
United States Olympic Committee from using performance-
enhancing drugs, or performance-enhancing genetic
modifications accomplished through gene-doping;
(4) serve as the United States representative responsible
for coordination with other anti-doping organizations
coordinating amateur athletic competitions recognized by the
United States Olympic Committee to ensure the integrity of
athletic competition, the health of the athletes and the
prevention of use of performance-enhancing drugs, or
performance-enhancing genetic modifications accomplished
through gene-doping by United States amateur athletes; and
(5) permanently include ``gene doping'' among any list of
prohibited substances adopted by the Agency.
SEC. 702. RECORDS, AUDIT, AND REPORT.
(a) Records.--The United States Anti-Doping Agency shall
keep correct and complete records of account.
(b) Report.--The United States Anti-Doping Agency shall
submit an annual report to Congress which shall include--
(1) an audit conducted and submitted in accordance with
section 10101 of title 36, United States Code; and
(2) a description of the activities of the agency.
SEC. 703. AUTHORIZATION OF APPROPRIATIONS.
There are authorized to be appropriated to the United
States Anti-Doping Agency--
(1) for fiscal year 2007, $9,700,000;
(2) for fiscal year 2008, $10,300,000;
(3) for fiscal year 2009, $10,600,000;
(4) for fiscal year 2010, $11,000,000; and
(5) for fiscal year 2011, $11,500,000.
TITLE VIII--DRUG-FREE COMMUNITIES
SEC. 801. REAUTHORIZATION.
(a) In General.--Section 1024(a) of the Drug-Free
Communities Act of 1997 (21 U.S.C. 1524(a)) is amended--
(1) in paragraph (9), by striking ``and'' after the
semicolon;
(2) in paragraph (10), by striking the period and inserting
a semicolon; and
(3) by adding at the end the following:
``(11) $109,000,000 for fiscal year 2008;
``(12) $114,000,000 for fiscal year 2009;
``(13) $119,000,000 for fiscal year 2010;
``(14) $124,000,000 for fiscal year 2011; and
``(15) $129,000,000 for fiscal year 2012.''.
(b) Administration Costs.--Section 1024(b) of the Drug-Free
Communities Act of 1997 (21 U.S.C. 1524(b)) is amended to
read as follows:
``(b) Administrative Costs.--
``(1) Limitation.--Not more than 3 percent of the funds
appropriated for this chapter may be used by the Office of
National Control Policy to pay for administrative costs
associated with their responsibilities under the chapter.
``(2) Designated agency.--The agency delegated to carry out
this program under section 1031(d) may use up to 5 percent of
the funds allocated for grants under this chapter for
administrative costs associated with carrying out the
program.''.
SEC. 802. SUSPENSION OF GRANTS.
(a) In General.--Section 1032(b) of the Drug-Free
Communities Act of 1997 (21 U.S.C. 1532(b)) is amended by
adding at the end the following:
``(4) Process for suspension.--A grantee shall not be
suspended or terminated under paragraph (1)(A)(ii),
(2)(A)(iii), or (3)(E) unless that grantee is afforded a
fair, timely, and independent appeal prior to such suspension
or termination.''.
(b) Report to Congress.--Not later than 60 days after the
date of enactment of this Act, the Director of the Office of
National Drug Control Policy shall submit to Congress a
report detailing the appeals process required by section
1032(b)(4) of the Drug-Free Communities Act of 1997, as added
by subsection (a).
SEC. 803. GRANT AWARD INCREASE.
Subsections (b)(1)(A)(iv), (b)(2)(C)(i), and (b)(3)(F) of
section 1032 of the Drug-Free Communities Act of 1997 (21
U.S.C. 1532) are amended by striking ``$100,000'' and
inserting ``$125,000''.
SEC. 804. PROHIBITION ON ADDITIONAL ELIGIBILITY CRITERIA.
Section 1032(a) of the Drug-Free Communities Act of 1997
(21 U.S.C. 1532(a)) is amended by adding at the end the
following:
``(7) Additional criteria.--The Director shall not impose
any eligibility criteria on new applicants or renewal
grantees not provided in this chapter.''.
SEC. 805. NATIONAL COMMUNITY ANTI-DRUG COALITION INSTITUTE.
Section 4 of Public Law 107-82 (21 U.S.C. 1521 note),
reauthorizing the Drug-Free Communities Support Program, is
amended--
(1) by amending subsection (a) to read as follows:
``(a) In General.--The Director of the Office of National
Drug Control Policy shall, using amounts authorized to be
appropriated by subsection (d), make a directed grant to
Community Anti-Drug Coalitions of America to provide for the
continuation of the National Community Anti-drug Coalition
Institute.'';
(2) by striking subsection (b) and redesignating
subsections (c) and (d) as (b) and (c), respectively; and
(3) in subsection (c), as redesignated by paragraph (2), by
adding at the end the following:
``(4) For each of the fiscal years 2008 through 2012,
$2,000,000.''.
[[Page H8960]]
TITLE IX--NATIONAL GUARD COUNTERDRUG SCHOOLS
SEC. 901. NATIONAL GUARD COUNTERDRUG SCHOOLS.
(a) Authority To Operate.--Under such regulations as the
Secretary of Defense may prescribe, the Chief of the National
Guard Bureau may establish and operate, or provide financial
assistance to the States to establish and operate, not more
than 5 schools (to be known generally as ``National Guard
counterdrug schools'').
(b) Purpose.--The purpose of the National Guard counterdrug
schools shall be the provision by the National Guard of
training in drug interdiction and counterdrug activities and
drug demand reduction activities to personnel of the
following:
(1) Federal agencies.
(2) State, local, and tribal law enforcement agencies.
(3) Community-based organizations engaged in such
activities.
(4) Other non-Federal governmental and private entities and
organizations engaged in such activities.
(c) Counterdrug Schools Specified.--The National Guard
counterdrug schools operated under the authority in
subsection (a) are as follows:
(1) The National Interagency Civil-Military Institute
(NICI), San Luis Obispo, California.
(2) The Multi-Jurisdictional Counterdrug Task Force
Training (MCTFT), St. Petersburg, Florida.
(3) The Midwest Counterdrug Training Center (MCTC),
Johnston, Iowa.
(4) The Regional Counterdrug Training Academy (RCTA),
Meridian, Mississippi.
(5) The Northeast Regional Counterdrug Training Center
(NCTC), Fort Indiantown Gap, Pennsylvania.
(d) Use of National Guard Personnel.--
(1) In general.--To the extent provided for in the State
drug interdiction and counterdrug activities plan of a State
in which a National Guard counterdrug school is located,
personnel of the National Guard of that State who are ordered
to perform full-time National Guard duty authorized under
section 112(b) of that title 32, United States Code, may
provide training referred to in subsection (b) at that
school.
(2) Definition.--In this subsection, the term ``State drug
interdiction and counterdrug activities plan'', in the case
of a State, means the current plan submitted by the Governor
of the State to the Secretary of Defense under section 112 of
title 32, United States Code.
(e) Treatment Under Authority To Provide Counterdrug
Support.--The provisions of section 1004 of the National
Defense Authorization Act for Fiscal Year 1991 (Public Law
101-510; 10 U.S.C. 374 note) shall apply to any activities of
a National Guard counterdrug school under this section that
are for an agency referred to in subsection (a) of such
section 1004 and for a purpose set forth in subsection (b) of
such section 1004.
(f) Annual Reports on Activities.--
(1) In general.--Not later than February 1 each year, the
Secretary of Defense shall submit to Congress a report on the
activities of the National Guard counterdrug schools during
the preceding year.
(2) Contents.--Each report under paragraph (1) shall set
forth the following:
(A) Funding.--The amount made available for each National
Guard counterdrug school during the fiscal year ending in the
year preceding the year in which such report is submitted.
(B) Activities.--A description of the activities of each
National Guard counterdrug school during the year preceding
the year in which such report is submitted.
(g) Authorization of Appropriations.--
(1) In general.--There is hereby authorized to be
appropriated for the Department of Defense for the National
Guard for each of fiscal years 2006 through 2010, $30,000,000
for purposes of the National Guard counterdrug schools in
such fiscal year.
(2) Construction.--The amount authorized to be appropriated
by paragraph (1) for a fiscal year is in addition to any
other amount authorized to be appropriated for the Department
of Defense for the National Guard for such fiscal year.
TITLE X--NATIONAL METHAMPHETAMINE INFORMATION CLEARINGHOUSE ACT OF 2006
SEC. 1001. SHORT TITLE.
This title may be cited as the ``National Methamphetamine
Information Clearinghouse Act of 2006''.
SEC. 1002. DEFINITIONS.
In this title--
(1) the term ``Council'' means the National Methamphetamine
Advisory Council established under section 1003(b)(1);
(2) the term ``drug endangered children'' means children
whose physical, mental, or emotional health are at risk
because of the production, use, or other effects of
methamphetamine production or use by another person;
(3) the term ``National Methamphetamine Information
Clearinghouse'' or ``NMIC'' means the information
clearinghouse established under section 1003(a); and
(4) the term ``qualified entity'' means a State, local, or
tribal government, school board, or public health, law
enforcement, nonprofit, community anti-drug coalition, or
other nongovernmental organization providing services related
to methamphetamines.
SEC. 1003. ESTABLISHMENT OF CLEARINGHOUSE AND ADVISORY
COUNCIL.
(a) Clearinghouse.--There is established, under the
supervision of the Attorney General of the United States, an
information clearinghouse to be known as the National
Methamphetamine Information Clearinghouse.
(b) Advisory Council.--
(1) In general.--There is established an advisory council
to be known as the National Methamphetamine Advisory Council.
(2) Membership.--The Council shall consist of 10 members
appointed by the Attorney General--
(A) not fewer than 3 of whom shall be representatives of
law enforcement agencies;
(B) not fewer than 4 of whom shall be representatives of
nongovernmental and nonprofit organizations providing
services or training and implementing programs or strategies
related to methamphetamines; and
(C) 1 of whom shall be a representative of the Department
of Health and Human Services.
(3) Period of appointment; vacancies.--Members shall be
appointed for 3 years. Any vacancy in the Council shall not
affect its powers, but shall be filled in the same manner as
the original appointment.
(4) Personnel matters.--
(A) Travel expenses.--The members of the Council shall be
allowed travel expenses, including per diem in lieu of
subsistence, at rates authorized for employees of agencies
under subchapter I of chapter 57 of title 5, United States
Code, while away from their homes or regular places of
business in the performance of services for the Council.
(B) No compensation.--The members of the Council shall not
receive compensation for the performance of the duties of a
member of the Council.
SEC. 1004. NMIC REQUIREMENTS AND REVIEW.
(a) In General.--The NMIC shall promote sharing information
regarding successful law enforcement, treatment,
environmental, prevention, social services, and other
programs related to the production, use, or effects of
methamphetamine and grants available for such programs.
(b) Components.--The NMIC shall include--
(1) a toll-free number; and
(2) a website that provides a searchable database, which--
(A) provides information on the short-term and long-term
effects of methamphetamine use;
(B) provides information regarding methamphetamine
treatment and prevention programs and strategies and programs
for drug endangered children, including descriptions of
successful programs and strategies and contact information
for such programs and strategies;
(C) provides information regarding grants for
methamphetamine-related programs, including contact
information and links to websites;
(D) allows a qualified entity to submit items to be posted
on the website regarding successful public or private
programs or other useful information related to the
production, use, or effects of methamphetamine;
(E) includes a restricted section that may only be accessed
by a law enforcement organization that contains successful
strategies, training techniques, and other information that
the Council determines helpful to law enforcement agency
efforts to identify or combat the production, use or effects
of methamphetamine;
(F) allows public access to all information not in a
restricted section; and
(G) contains any additional information the Council
determines may be useful in identifying or combating the
production, use, or effects of methamphetamine.
Thirty days after the website in paragraph (2) is
operational, no funds shall be expended to continue the
website methresources.gov.
(c) Review of Posted Information.--
(1) In general.--Not later than 30 days after the date of
submission of an item by a qualified entity, the Council
shall review an item submitted for posting on the website
described in subsection (b)(2)--
(A) to evaluate and determine whether the item, as
submitted or as modified, meets the requirements for posting;
and
(B) in consultation with the Attorney General, to determine
whether the item should be posted in a restricted section of
the website.
(2) Determination.--Not later than 45 days after the date
of submission of an item, the Council shall--
(A) post the item on the website described in subsection
(b)(2); or
(B) notify the qualified entity that submitted the item
regarding the reason such item shall not be posted and
modifications, if any, that the qualified entity may make to
allow the item to be posted.
SEC. 1005. AUTHORIZATION OF APPROPRIATIONS.
There are authorized to be appropriated--
(1) for fiscal year 2007--
(A) $500,000 to establish the NMIC and Council; and
(B) such sums as are necessary for the operation of the
NMIC and Council; and
(2) for each of fiscal years 2008 and 2009, such sums as
are necessary for the operation of the NMIC and Council.
TITLE XI--MISCELLANEOUS PROVISIONS
SEC. 1101. REPEALS.
(a) Act.--Section 710 is repealed.
(b) Forfeiture Assets.--Section 6073 of the Assets
Forfeiture Amendments Act of 1988 (21 U.S.C. 1509) is
repealed.
[[Page H8961]]
SEC. 1102. CONTROLLED SUBSTANCES ACT AMENDMENTS.
Section 303(g)(2) of the Controlled Substances Act (21
U.S.C. 823(g)(2)) is amended--
(1) in subparagraph (B)(iii), by striking ``except that
the'' and inserting the following: ``unless, not sooner than
1 year after the date on which the practitioner submitted the
initial notification, the practitioner submits a second
notification to the Secretary of the need and intent of the
practitioner to treat up to 100 patients. A second
notification under this clause shall contain the
certifications required by clauses (i) and (ii) of this
subparagraph. The''; and
(2) in subparagraph (J)--
(A) in clause (i), by striking ``thereafter'' and all that
follows through the period and inserting ``thereafter.'';
(B) in clause (ii), by striking ``Drug Addiction Treatment
Act of 2000'' and inserting ``Office of National Drug Control
Policy Reauthorization Act of 2006''; and
(C) in clause (iii), by striking ``this paragraph should
not remain in effect, this paragraph ceases to be in effect''
and inserting ``subparagraph (B)(iii) should be applied by
limiting the total number of patients a practitioner may
treat to 30, then the provisions in such subparagraph
(B)(iii) permitting more than 30 patients shall not apply,
effective''.
SEC. 1103. REPORT ON LAW ENFORCEMENT INTELLIGENCE SHARING.
Not later than 180 days after the date of enactment of this
Act, the Director shall submit to Congress a report--
(1) evaluating existing and planned law enforcement
intelligence systems used by Federal, State, local, and
tribal law enforcement agencies responsible for drug
trafficking and drug production enforcement; and
(2) addressing--
(A) the current law enforcement intelligence systems used
by Federal, State, local, and tribal law enforcement
agencies;
(B) the compatibility of such systems in ensuring access
and availability of law enforcement intelligence to Federal,
State, local, and tribal law enforcement;
(C) the extent to which Federal, State, local, and tribal
law enforcement are sharing law enforcement intelligence
information to assess current threats and design appropriate
enforcement strategies; and
(D) the measures needed to ensure and to promote effective
information sharing among law enforcement intelligence
systems operated by Federal, State, local, and tribal law
enforcement agencies responsible for drug trafficking and
drug production enforcement.
SEC. 1104. REQUIREMENT FOR SOUTH AMERICAN HEROIN STRATEGY.
(a) In General.--Not later than 90 days after the date of
enactment of this Act, the Director, in coordination with the
Secretary of State, shall submit to Congress a comprehensive
strategy that addresses the increased threat from South
American heroin, and in particular Colombian heroin, and the
emerging threat from opium poppy grown in Peru and often
intended for transit to Columbia for processing into heroin.
(b) Contents.--The strategy submitted under subsection (a)
shall include--
(1) opium eradication efforts to eliminate the problem at
the source to prevent heroin from entering the stream of
commerce;
(2) interdiction and precursor chemical controls;
(3) demand reduction and treatment;
(4) alternative development programs, including direct
assistance to regional governments to demobilize and provide
alternative livelihoods to former members of insurgent or
other groups engaged in heroin, cocoa, or other illicit drug
production or trafficking;
(5) efforts to inform and involve local citizens in the
programs described in paragraphs (1) through (4), such as
through leaflets advertising rewards for information; and
(6) an assessment of the specific level of funding and
resources necessary to simultaneously address the threat from
South American heroin and the threat from Colombian and
Peruvian coca.
(c) Treatment of Classified or Law Enforcement Sensitive
Information.--Any content of the strategy submitted under
subsection (a) that involves information classified under
criteria established by an Executive order, or whose public
disclosure, as determined by the Director or the head of any
relevant Federal agency, would be detrimental to the law
enforcement of national security activities of any Federal,
foreign, or international agency, shall be presented to
Congress separately from the rest of the strategy.
SEC. 1105. MODEL ACTS.
(a) In General.--The Director of the Office of National
Drug Control Policy shall provide for or shall enter into an
agreement with a non-profit corporation that is described in
section 501(c)(3) of the Internal Revenue Code of 1986 and
exempt from tax under section 501(a) of such Code to--
(1) advise States on establishing laws and policies to
address alcohol and other drug issues, based on the model
State drug laws developed by the President's Commission on
Model State Drug Laws in 1993; and
(2) revise such model State drug laws and draft
supplementary model State laws to take into consideration
changes in the alcohol and drug abuse problems in the State
involved.
(b) Authorization of Appropriations.--There is authorized
to be appropriated to carry out this subsection $1,500,000
for each of fiscal years 2007 through 2011.
SEC. 1106. STUDY ON IATROGENIC ADDICTION ASSOCIATED WITH
PRESCRIPTION OPIOID ANALGESIC DRUGS.
(a) In General.--
(1) Study.--The Director of the Office of National Drug
Control Policy shall request the Institute of Medicine of the
National Academy of Sciences to enter into an agreement under
which the Institute agrees to study certain aspects of
iatrogenic addiction to prescription opioid analgesics
included in schedules II and III of the Controlled Substances
Act (21 U.S.C. 812).
(2) Iatrogenic addiction.--In this section, the term
``iatrogenic addiction'' means an addiction developed from
the use of an opioid analgesic by an individual with no
previous history of any addiction, who has lawfully obtained
and used the drug for a legitimate medical purpose by
administration from, or pursuant to the prescription or order
of, an individual practitioner acting in the usual course of
professional practice.
(b) Requirements.--The study conducted pursuant to this
section shall assess the current scientific literature to
determine, if possible--
(1) the rate of iatrogenic addiction associated with the
appropriate use of prescription drugs described in subsection
(a);
(2) the impact of iatrogenic addiction associated with the
appropriate use of prescription drugs described in subsection
(a) on the individual, the prescriber, other patients, and
society in general;
(3) the comparative abuse liability of prescription drugs
described in subsection (a) when used properly by the
ultimate user for a legitimate medical purpose; and
(4)(A) what types of prospective or retrospective studies
should be undertaken to determine the rate of iatrogenic
addiction associated with the appropriate use of the
prescription drugs described in subsection (a); and
(B) a feasible timeline for conducting and reporting such
studies, should the current state of the scientific
literature be insufficient to determine the rate, impact, and
comparative abuse liability of prescription drugs described
in subsection (a).
(c) Report.--Not later than 1 year after the date of
enactment of this Act, the Director of the Office of National
Drug Control Policy shall ensure that the agreement under
subsection (a) provides for the submission of a report to the
Congress on the status of the study conducted pursuant to
this section.
SEC. 1107. REQUIREMENT FOR STRATEGY TO STOP INTERNET
ADVERTISING OF PRESCRIPTION MEDICINES WITHOUT A
PRESCRIPTION.
Not later than 120 days after the date of the enactment of
this Act, the Director of the Office of National Drug Control
Policy shall submit to Congress a strategy to stop
advertisements that provide information about obtaining over
the Internet drugs (as defined in section 702(3) of the
Office of National Drug Control Policy Reauthorization Act of
1998) for which a prescription is required without the use of
such a lawful prescription.
SEC. 1108. REQUIREMENT FOR STUDY ON DIVERSION AND
INAPPROPRIATE USES OF PRESCRIPTION DRUGS.
Not later than 90 days after the date of enactment of this
Act, the Director of the Office of National Drug Control
Policy, in consultation with the Secretary of Health and
Human Services, shall submit to Congress a report that
includes a plan to conduct a study on the illegal diversion
and inappropriate uses of prescription drugs, including the
following:
(1) Methods to utilize both public use surveys that are in
existence as of the date of enactment of this Act and other
surveys to provide appropriate baseline data on the natural
history of diversion and abuse of prescription drugs that are
included in schedules under the Controlled Substances Act to
evaluate the extent and nature of potential problems with
such use to guide corrective actions which may reduce such
problems without unintentionally hindering access to these
drugs for legitimate medical purposes. Specifically, other
surveys to be considered are those that address the abuse of
these substances on a regional or national basis, and those
that address the diversion of these substances on a regional
or national basis.
(2) A scientifically based analysis of the relative
contribution of both innate and acquired genetic factors,
environmental factors, psychological factors, and drug
characteristics that contribute to addiction to prescription
drugs.
SEC. 1109. REQUIREMENT FOR AFGHAN HEROIN STRATEGY.
(a) In General.--Not later than 90 days after the date of
the enactment of this Act, the Director of the Office of
National Drug Control Policy shall submit to the Congress a
comprehensive strategy that addresses the increased threat
from Afghan heroin.
(b) Contents.--The strategy shall include--
(1) opium crop eradication efforts to eliminate the problem
at the source to prevent heroin from entering the stream of
commerce;
(2) destruction or other direct elimination of stockpiles
of heroin and raw opium, and heroin production and storage
facilities;
(3) interdiction and precursor chemical controls;
(4) demand reduction and treatment;
(5) alternative development programs;
(6) measures to improve cooperation and coordination
between Federal Government
[[Page H8962]]
agencies, and between such agencies, agencies of foreign
governments, and international organizations with
responsibility for the prevention of heroin production in, or
trafficking out of, Afghanistan; and
(7) an assessment of the specific level of funding and
resources necessary significantly to reduce the production
and trafficking of heroin.
(c) Treatment of Classified or Law Enforcement Sensitive
Information.--Any content of the strategy that involves
information classified under criteria established by an
Executive order, or whose public disclosure, as determined by
the Director or the head of any relevant Federal agency,
would be detrimental to the law enforcement or national
security activities of any Federal, foreign, or international
agency, shall be presented to Congress separately from the
rest of the strategy.
SEC. 1110. REQUIREMENT FOR SOUTHWEST BORDER COUNTERNARCOTICS
STRATEGY.
(a) In General.--Not later than 120 days after the date of
enactment of this Act, and every 2 years thereafter, the
Director of National Drug Control Policy shall submit to the
Congress a Southwest Border Counternarcotics Strategy.
(b) Purposes.--The Southwest Border Counternarcotics
Strategy shall--
(1) set forth the Government's strategy for preventing the
illegal trafficking of drugs across the international border
between the United States and Mexico, including through ports
of entry and between ports of entry on that border;
(2) state the specific roles and responsibilities of the
relevant National Drug Control Program agencies (as defined
in section 702 of the Office of National Drug Control Policy
Reauthorization Act of 1998 (21 U.S.C. 1701)) for
implementing that strategy; and
(3) identify the specific resources required to enable the
relevant National Drug Control Program agencies to implement
that strategy.
(c) Specific Content Related to Drug Tunnels Between the
United States and Mexico.--The Southwest Border
Counternarcotics Strategy shall include--
(1) a strategy to end the construction and use of tunnels
and subterranean passages that cross the international border
between the United States and Mexico for the purpose of
illegal trafficking of drugs across such border; and
(2) recommendations for criminal penalties for persons who
construct or use such a tunnel or subterranean passage for
such a purpose.
(d) Consultation With Other Agencies.--The Director shall
issue the Southwest Border Counternarcotics Strategy in
consultation with the heads of the relevant National Drug
Control Program agencies.
(e) Limitation.--The Southwest Border Counternarcotics
Strategy shall not change existing agency authorities or the
laws governing interagency relationships, but may include
recommendations about changes to such authorities or laws.
(f) Report to Congress.--The Director shall provide a copy
of the Southwest Border Counternarcotics Strategy to the
appropriate congressional committees (as defined in section
702 of the Office of National Drug Control Policy
Reauthorization Act of 1998 (21 U.S.C. 1701)), and to the
Committee on Armed Services and the Committee on Homeland
Security of the House of Representatives, and the Committee
on Homeland Security and Governmental Affairs and the
Committee on Armed Services of the Senate.
(g) Treatment of Classified or Law Enforcement Sensitive
Information.--Any content of the Southwest Border
Counternarcotics Strategy that involves information
classified under criteria established by an Executive order,
or whose public disclosure, as determined by the Director or
the head of any relevant National Drug Control Program
agency, would be detrimental to the law enforcement or
national security activities of any Federal, State, local, or
tribal agency, shall be presented to Congress separately from
the rest of the strategy.
SEC. 1111. REQUIREMENT FOR SCIENTIFIC STUDY OF MYCOHERBICIDE
IN ILLICIT DRUG CROP ERADICATION.
(a) Requirement.--Not later than 90 days after the date of
enactment of this Act, the Director of the Office of National
Drug Control Policy shall submit to the Congress a report
that includes a plan to conduct, on an expedited basis, a
scientific study of the use of mycoherbicide as a means of
illicit drug crop elimination by an appropriate Government
scientific research entity, including a complete and thorough
scientific peer review. The study shall include an evaluation
of the likely human health and environmental impacts of
mycoherbicides derived from fungus naturally existing in the
soil.
(b) Study.--The study required by this section shall be
conducted in United States territory and not in any foreign
country.
SEC. 1112. REQUIREMENT FOR STUDY OF STATE PRECURSOR CHEMICAL
CONTROL LAWS.
(a) Study.--The Director of National Drug Control Policy,
in consultation with the National Alliance for Model State
Drug Laws, shall conduct a study of State laws with respect
to precursor chemical controls.
(b) Report.--Not later than 6 months after the date of the
enactment of this Act, the Director of National Drug Control
Policy shall submit a report to Congress on the results of
the study under subsection (a), including--
(1) a comparison of the State laws studied and the
effectiveness of each such law; and
(2) a list of best practices observed with respect to such
laws.
SEC. 1113. REQUIREMENT FOR STUDY OF DRUG ENDANGERED CHILDREN
PROGRAMS.
(a) Study.--The Director of National Drug Control Policy
shall conduct a study of methamphetamine-related activities
that are conducted by different Drug Endangered Children
programs administered by States.
(b) Report.--Not later than 6 months after the date of the
enactment of this Act, the Director of National Drug Control
Policy shall submit to Congress a report on the results of
the study under subsection (a). Such report shall include--
(1) an analysis of the best practices of the activities
studied; and
(2) recommendations for establishing a national policy to
address drug endangered children, based on the Drug
Endangered Children programs administered by States.
(c) Definitions.--In this section--
(1) the term ``methamphetamine-related activity'' means any
activity related to the production, use, or effects of
methamphetamine; and
(2) the term ``drug endangered children'' means children
whose physical, mental, or emotional health are at risk
because of the production, use, or effects of methamphetamine
by another person.
SEC. 1114. STUDY ON DRUG COURT HEARINGS IN NONTRADITIONAL
PLACES.
(a) Finding.--Congress finds that encouraging drug courts
and schools to enter into partnerships that allow students to
see the repercussions of drug abuse by non-violent offenders
may serve as a strong deterrent and promote demand reduction.
(b) Study.--The Director of the Office of National Drug
Control Policy shall conduct a study on drug court programs
that conduct hearings in nontraditional public places, such
as schools. At a minimum, the study shall evaluate similar
programs in operation, such as the program operated in the
Fourth Judicial District Drug Court, in Washington County,
Arkansas.
(c) Requirement.--At the same time the President submits to
Congress the National Drug Control Strategy due February 1,
2007, pursuant to section 706 of the Office of National Drug
Control Policy Reauthorization Act of 1998, the President
shall submit to Congress a report on the study conducted
under subsection (b). The report shall include an evaluation
of the results of the study and such recommendations as the
President considers appropriate.
(d) Demand Reduction.--In this section, the term ``demand
reduction'' has the meaning provided in section 702(1) of the
Office of National Drug Control Policy Reauthorization Act of
1998 (21 U.S.C. 1701(1)).
SEC. 1115. REPORT ON TRIBAL GOVERNMENT PARTICIPATION IN HIDTA
PROCESS.
(a) Report Requirement.--The Director of the Office of
National Drug Control Policy shall prepare a report for
Congress on the representation of tribal governments in the
High Intensity Drug Trafficking Areas Program and in high
intensity drug trafficking areas designated under that
Program. The report shall include--
(1) a list of the tribal governments represented in the
Program and a description of the participation by such
governments in the Program;
(2) an explanation of the rationale for the level of
representation by such governments; and
(3) recommendations by the Director for methods for
increasing the number of tribal governments represented in
the Program.
(b) Deadline.--The report prepared under subsection (a)
shall be submitted not later than 1 year after the date of
the enactment of this Act.
(c) Definition.--In this section, the term ``High Intensity
Drug Trafficking Areas Program'' means the program
established under section 707 of the Office of National Drug
Control Policy Reauthorization Act of 1998 (21 U.S.C. 1706)
SEC. 1116. REPORT ON SCHOOL DRUG TESTING.
(a) Report Requirement.--The Director of National Drug
Control Policy shall prepare a report on drug testing in
schools. The report shall include a list of secondary schools
that have initiated drug testing from among those schools
that have attended conferences on drug testing sponsored by
the Office of National Drug Control Policy.
(b) Deadline.--Not later than 120 days after the date of
the enactment of this Act, the Director of National Drug
Control Policy shall submit to Congress the report required
under subsection (a).
SEC. 1117. REPORT ON ONDCP PERFORMANCE BONUSES.
(a) Report Requirement.--The Director of National Drug
Control Policy shall prepare a report on performance bonuses
at the Office of National Drug Control Policy. The report
shall include a list of employees who received performance
bonuses, and the amount of such bonuses, for the period
beginning on October 1, 2004, and ending on the date of
submission of the report.
(b) Deadline.--Not later than 120 days after the date of
the enactment of this Act, the Director of National Drug
Control Policy shall submit to Congress the report required
under subsection (a).
SEC. 1118. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP
OF ALL FEDERAL ADVERTISING OR OTHER
COMMUNICATION MATERIALS.
Section 712 is amended to read as follows:
[[Page H8963]]
``SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP
OF ALL FEDERAL ADVERTISING OR OTHER
COMMUNICATION MATERIALS.
``(a) Requirement.--Each advertisement or other
communication paid for by the Office, either directly or
through a contract awarded by the Office, shall include a
prominent notice informing the target audience that the
advertisement or other communication is paid for by the
Office.
``(b) Advertisement or Other Communication.--In this
section, the term `advertisement or other communication'
includes--
``(1) an advertisement disseminated in any form, including
print or by any electronic means; and
``(2) a communication by an individual in any form,
including speech, print, or by any electronic means.''.
SEC. 1119. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL
PARTNERSHIPS TO COERCE ABSTINENCE IN CHRONIC
HARD-DRUG USERS UNDER COMMUNITY SUPERVISION
THROUGH THE USE OF DRUG TESTING AND SANCTIONS.
At the end of the Act, insert the following:
``SEC. 716. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL
PARTNERSHIPS TO COERCE ABSTINENCE IN CHRONIC
HARD-DRUG USERS UNDER COMMUNITY SUPERVISION
THROUGH THE USE OF DRUG TESTING AND SANCTIONS.
``(a) Awards Required.--The Director shall make competitive
awards to fund demonstration programs by eligible
partnerships for the purpose of reducing the use of illicit
drugs by chronic hard-drug users living in the community
while under the supervision of the criminal justice system.
``(b) Use of Award Amounts.--Award amounts received under
this section shall be used--
``(1) to support the efforts of the agencies,
organizations, and researchers included in the eligible
partnership;
``(2) to develop and field a drug testing and graduated
sanctions program for chronic hard-drug users living in the
community under criminal justice supervision; and
``(3) to assist individuals described in subsection (a) by
strengthening rehabilitation efforts through such means as
job training, drug treatment, or other services.
``(c) Eligible Partnership Defined.--In this section, the
term `eligible partnership' means a working group whose
application to the Director--
``(1) identifies the roles played, and certifies the
involvement of, two or more agencies or organizations, which
may include--
``(A) State, local, or tribal agencies (such as those
carrying out police, probation, prosecution, courts,
corrections, parole, or treatment functions);
``(B) Federal agencies (such as the Drug Enforcement
Agency, the Bureau of Alcohol, Tobacco, Firearms, and
Explosives, and United States Attorney offices); and
``(C) community-based organizations;
``(2) includes a qualified researcher;
``(3) includes a plan for using judicial or other criminal
justice authority to administer drug tests to individuals
described in subsection (a) at least twice a week, and to
swiftly and certainly impose a known set of graduated
sanctions for non-compliance with community-release
provisions relating to drug abstinence (whether imposed as a
pre-trial, probation, or parole condition or otherwise);
``(4) includes a strategy for responding to a range of
substance use and abuse problems and a range of criminal
histories;
``(5) includes a plan for integrating data infrastructure
among the agencies and organizations included in the eligible
partnership to enable seamless, real-time tracking of
individuals described in subsection (a);
``(6) includes a plan to monitor and measure the progress
toward reducing the percentage of the population of
individuals described in subsection (a) who, upon being
summoned for a drug test, either fail to show up or who test
positive for drugs.
``(d) Reports to Congress.--
``(1) Interim report.--Not later than June 1, 2009, the
Director shall submit to Congress a report that identifies
the best practices in reducing the use of illicit drugs by
chronic hard-drug users, including the best practices
identified through the activities funded under this section.
``(2) Final report.--Not later than June 1, 2010, the
Director shall submit to Congress a report on the
demonstration programs funded under this section, including
on the matters specified in paragraph (1).
``(e) Authorization of Appropriations.--There is authorized
to be appropriated to carry out this section $4,900,000 for
each of fiscal years 2007 through 2009.''.
SEC. 1120. POLICY RELATING TO SYRINGE EXCHANGE PROGRAMS.
Section 703(a) (21 U.S.C. 1702(a)) is amended by adding at
the end the following:
``When developing the national drug control policy, any
policy of the Director relating to syringe exchange programs
for intravenous drug users shall be based on the best
available medical and scientific evidence regarding their
effectiveness in promoting individual health and preventing
the spread of infectious disease, and their impact on drug
addiction and use. In making any policy relating to syringe
exchange programs, the Director shall consult with the
National Institutes of Health and the National Academy of
Sciences.''.
The SPEAKER pro tempore. Pursuant to the rule, the gentleman from
Indiana (Mr. Souder) and the gentleman from Maryland (Mr. Cummings)
each will control 20 minutes.
The Chair recognizes the gentleman from Indiana.
General Leave
Mr. SOUDER. Madam Speaker, I ask unanimous consent that all Members
may have 5 legislative days within which to revise and extend their
remarks and include extraneous material on the bill under
consideration.
The SPEAKER pro tempore. Is there objection to the request of the
gentleman from Indiana?
There was no objection.
Mr. SOUDER. Madam Speaker, I yield myself such time as I may consume.
Madam Speaker, I would first like to thank Government Reform Chairman
Tom Davis and Ranking Member Henry Waxman for working with us in the
Drug Policy Subcommittee and gaining their support and assistance in
passing this bipartisan bill.
It is tough to pass bipartisan bills, particularly major legislation
like this, at this time of year and in general. This authorization
program is multiyear, $530 million directly and hundreds of millions
more in some programs that were added to the original ONDCP bill, and
to do something like that unanimously and have it be worked through
both bodies has been an incredible accomplishment and an adventure.
I would also like to thank Judiciary Chairman Sensenbrenner, as well
as the minority, for waiving the right to go to the Judiciary
Committee. I know that is rare, but in our negotiations with the
Senate, we had multiple changes over the last few days, and that was a
very important waiver. His staff and the staff of Senator Specter in
the Senate have been very important allies in moving this bill. Also
Senators Grassley, Biden, Leahy and Levin have made multiple changes in
this bill in the last few days, all of which I think have helped
improve this bill. I very much appreciate the bipartisan spirit with
which we are trying to pass anti-drug legislation.
Of course my friend and colleague, Congressman Elijah Cummings, the
ranking member, and I have had a great working relationship these past
few years and have been able to tackle one of the toughest issues that
is hitting both urban America, suburban America and rural America,
together, and build a very close friendship during these years too and
a passion. I know from his experience in Baltimore seeing it firsthand
as a State legislator and as a resident in the communities so hard hit,
he brought a passion to this issue that has been very important. It has
been a real privilege working together during this period.
I now would like to read my opening statement.
Across America, individuals, families and communities continue to be
devastated by the scourge of drug abuse, and it remains one of the most
pressing and unforgiving problems our country faces. This bill is
largely the same language that the House passed on March 9 on a vote of
399-5, with some improvements that came from negotiations with the
other body and the administration.
It is a forceful and bipartisan recommitment to our broad national
efforts to control drug abuse and to renew our support for strong
leadership from the Office of National Drug Control Policy, often known
as the Drug Czar. By renewing this authorization, we believe we will
soon see an even better coordination of the President's strategy to
demonstrably reduce drug abuse by America's young people and to control
its sad consequences.
This reauthorization will preserve and improve our anti-drug efforts
in a number of ways. It will preserve the success of the High Intensity
Drug Trafficking Areas, or HIDTA programs.
As the ONDCP's principal law enforcement program, HIDTA brings
Federal, State, and local law enforcement together in specific high
trafficking areas for sharing of intelligence and joint enforcement
actions. It is perhaps the best model of governments working together
in such a coordinated way, in a model that in Homeland Security we are
attempting to duplicate but thus far have not had the same success.
This bill keeps HIDTA in ONDCP where it belongs, focusing on
dismantling drug trafficking organizations.
[[Page H8964]]
It also provides a process for redirecting scarce funds to those
HIDTA regions where the need is greatest, as well as enacting much-
needed performance measurements. It will refocus the National Youth
Anti-Drug Media Campaign, which all of us see in radio and television
and it is our principal program to reach young people on prevention.
This bill clarifies the purposes of this campaign, establishing that it
is intended for mass media advertising to direct and steer young people
away from drug abuse. This will turn the campaign away from projects
not related to such mass media advertising.
It will strengthen the Southwest Border Counternarcotics Strategy.
Perhaps you have heard that we don't exactly control the southwest
border at this time. Increasingly, the drug trade and all its attendant
violence and corruption is concentrating on the southwest border.
This bill requires the director of ONDCP to issue within 120 days of
enactment a strategy identifying how the government will deal with this
narcotics problem on the border, the roles of the various agencies in
it, and the resources needed.
Quite frankly, it is astounding that such a southwest border strategy
does not currently exist. It will elevate the rank and status of the
ONDCP director because the director is tasked with coordinating the
drug control efforts of numerous agencies, including Cabinet-level
Departments.
This bill designates that he has the same rank and status as a
Cabinet officer. This does not interfere with the President's authority
to determine the makeup of his Cabinet, but it does assure that the
director will be able to work Department heads as an equal, which is
critical when you are working with State, Defense, Judiciary, Homeland
Security and the many other agencies. This is essential if he is to
have full cooperation and teamwork from these other executive offices.
It will improve effectiveness and accountability in drug treatment.
The bill will enhance drug treatment programs by requiring, for the
first time, a uniform system of evaluating the success of drug
treatment.
Further, it will prevent the director from certifying any Federal
budget request related to drug treatment that does not provide for
adequate result and accountability measures.
I want to address a few other things that were added over the last
few days with the Senate. One is the Drug Free Communities Act. This
was developed by former Congressman Portman and Congressman Levin here
and has been backed widely in this body.
It usually has a separate reauthorization. It has been put into this
bill. It is already under ONDCP, but it usually moves in a separate
bill. It has been combined with this bill so we are also reauthorizing
the Drug Free Communities bill, which is absolutely one of the most
effective grass-roots prevention programs.
It, along with drug free schools and the national media campaign, are
our only prevention efforts. It reauthorizes the National Guard
counterdrug schools, which uses our National Guard in different States.
In Indiana they are very active in going into schools and is a
supplement to the Drug Free Schools program. And it authorizes the U.S.
Anti-doping Agency, which has been very critical in the steroids fight
and something we have been pushing for to get national measurements and
a more aggressive attitude towards abuse of steroids among young
people, and this authorizes that agency.
I once again want to thank all of those involved in this,
particularly Ranking Member Cummings, Chairman Tom Davis, and Ranking
Member Waxman of the full committee.
Madam Speaker, I reserve the balance of my time.
Mr. CUMMINGS. Madam Speaker, I yield myself such time as I may
consume.
Madam Speaker, I rise in strong support of H.R. 6344, as amended by
the amendment of the gentleman from Indiana (Mr. Souder). This bill to
reauthorize the Office of National Drug Control Policy and related
anti-drug programs is the product of a bipartisan and bicameral process
that began more than 3 years ago in the Government Reform Subcommittee
on Criminal Justice, Drug Policy and Human Resources, on which I serve
as the ranking minority member. For nearly that period of time, the
office has operated without legislative authorization.
I want to again thank and congratulate Chairman Souder. He talked
about my passion. I had an opportunity to see his when we visited his
district. He has spent just a phenomenal amount of time on this
legislation and spent a lot of time on this problem that we suffer from
in this country, and I want to thank him for his leadership, and his
very strong leadership at that.
I also want to thank our full committee chairman, Tom Davis, and the
Government Reform ranking member, Mr. Henry Waxman, for their strong
leadership and cooperation in shaping a bill that we were able to
report out of committee and pass on the House floor with strong
bipartisan support.
{time} 1600
This legislation incorporates additions and modifications negotiated
with the Senate Republicans and Democrats, most notably Senators
Grassley, Hatch, Biden, Leahy, and Levin.
At its core, the bill before us today is substantially the same as
the legislation passed by the House on March 9. The bill reauthorizes
the drug czar's office for 5 years and also reauthorizes several key
anti-drug programs managed by ONDCP, including the National Youth Anti-
Drug Media Campaign, the High Intensity Drug Trafficking Areas, or
HIDTA program, and the Counterdrug Technology Assessment Center. In
addition to authorizing funding for these programs, the bill contains
provisions to strengthen them and make them more accountable.
ONDCP, as the central coordinating body for drug control strategy in
the White House, plays a vital role in shaping the Federal response to
a national drug problem that claims more than 20,000 American lives
each year. Through its formulation of the National Drug Control
Strategy and its authority to certify the drug control budgets of
agencies throughout the executive branch, ONDCP provides critical
guidance and support to our efforts to address illegal drug abuse
through programs in the areas of prevention, treatment, domestic law
enforcement, interdiction, and international supply reduction efforts.
We are taking an important step by reauthorizing the drug czar's office
today.
I am especially pleased that this bill preserves bipartisan
agreements achieved through good faith negotiations during committee
consideration of the bill, including a provision to ensure that funds
for the National Youth Anti-Drug Media Campaign are not used to
advocate for or against any candidate or legislative or regulatory
measure.
I am also pleased that we will finally pass the Dawson Family
Community Protection Act which authorizes $7 million of HIDTA program
funds to be devoted to supporting efforts to improve safety and
facilitate cooperation with police and communities ravaged by drug
violence.
This provision memorializes the courageous efforts of Angela Dawson,
a Baltimore City resident, who along with her husband and five children
lost her life when a drug dealer fire-bombed the family's home in
retaliation for Ms. Dawson's reporting of drug distribution activities
in the immediate vicinity of her home. I might add that Ms. Dawson's
home is within a mile of my home.
HIDTA plays a vital role in combating drug trafficking in many areas
of the country, and this provision will help to ensure that funds are
available to address urgent threats to community safety due to drug
violence.
The amendments adopted by the other body augment and mainly improve
upon the House-passed bill. This bill adds reauthorization of the Drug-
Free Communities Support Program, one of the most popular and effective
Federal drug prevention programs that we have. One other addition
included in this bill also deserves particular mention.
The provision proposed by Senator Levin would amend the Controlled
Substances Act to increase from 30 to 100 the number of patients to
whom a doctor can prescribe buprenorphine, an extremely effective drug
for the use of opiate addiction. This important and welcome change will
have a tremendous impact in places like my own city
[[Page H8965]]
of Baltimore where opiate addiction is far too common and access to
treatment is far too limited. The bill would immediately triple the
capacity of physicians to prescribe this drug for patients with opiate
addiction and should have a substantial impact.
The substitute amendment implements two further changes negotiated
with the Senate in recent days. The first would modify a provision in
the House-passed bill calling for a study of mycoherbicides, requiring
that any testing be conducted inside the United States. The second
would restore a provision offered by Mr. Waxman that would require
ONDCP to consult with the National Institutes of Health and the
National Academy of Sciences when formulating policy on syringe
exchange programs aimed at preventing HIV transmission among injection
drug users. The provision calls for ONDCP to base any decisions on the
scientific evidence regarding the efficacy of syringe exchange and its
impact on drug use.
Madam Speaker, the devastating impact of drugs on communities
throughout this Nation is difficult to overstate. In some communities,
drugs are a quiet, invisible, disruptive force. In others, as in the
case of America's inner cities and rural communities afflicted by meth,
it is impossible not to see, and it is impossible not to feel the pain.
But no community is completely untouched or immune from this problem.
I am confident that this bill will preserve and strengthen our
Nation's most essential tools for fighting the good fight against drug
abuse and related crime and social problems.
I am also very pleased about the provisions with regard to
accountability for drug treatment. Mr. Souder and I have agreed over
and over again and done everything in our power to make sure that if
there is going to be drug treatment, that that drug treatment be
effective and efficient. We wanted to make sure that those who go into
treatment came out better off than what they went in.
One of the things that I have discovered as an elected official and
talking to many addicts is they go into drug treatment, and they feel
they have not been treated properly or that the treatment has not been
effective. That makes them reluctant to go into treatment again if need
be, and at the same time, many of them would not have gotten better.
That is not to take away from the many, many great organizations that
are doing a great job of treating drug-addicted folks, but we just want
to make sure that when America's taxpayers' dollars are spent, that
they are spent, again, in an effective and efficient manner, but we
also want something else. We want to make sure that those people who
find themselves in the clutches of drug addiction are able to depend
upon treatment that can best help them.
So I applaud my colleagues on both sides of the aisle and in both
Houses for their cooperative efforts, and I again want to thank Mr.
Souder for all the hard work. We have come now to what appears to be an
end to a long journey, but I am hopeful that what we have done in this
bill will affect generations yet unborn, for there are so many people
that will never know what we were able to accomplish in this
legislation, but they will be affected and they will be able to raise
their families, hopefully get back to work, do the things that
productive citizens do, and perhaps, just perhaps, another generation
of folk who may have gone into drugs, we may have just prevented some
of that.
Madam Speaker, I reserve the balance of my time.
Mr. SOUDER. Madam Speaker, I yield myself such time as I may consume.
I wanted to make a couple of additional comments before I yield back
fully. This is a very comprehensive bill. It includes many programs
that Members are familiar with in their districts but they may not have
realized was under the Office of National Drug Control Policy.
One is the Counterdrug Technology Assessment Center. That is the
primary resource of the United States Government that transfers
technology to your local law enforcement. It has also been a great
model. This bill requires it to be coordinated more closely with
homeland security.
Quite frankly, I think one of the challenges in the homeland security
is to make sure that they do what we have done in narcotics
enforcement. And that is, if a local small town wants certain equipment
because they think it is a fancy gadget, there is a review process that
says that is not really what you need; this is more likely to effect
and impact the type of narcotics enforcement you need in your
community. But it is the primary transfer program for technology and a
great model, and it reauthorizes that.
Also, we have had an exasperating 3-year fight with the drug czar
over the lack of coordination in this administration on
methamphetamine. There is a section here, approximately 4\1/2\ pages
long, in the National Methamphetamine Information Clearinghouse Act.
While the Combat Meth Act we passed in coordination with many State
acts have at least leveled off and in some States resulted, actually
resulted in a drop in the so-called mom-and-pop labs that are home
grown, in some States they are still coming in. Florida has had an
expansion. Some of this is to moving to Internet and some to crystal
meth.
We have had no clearinghouse in the United States Government that
worked with meth. This bill will add, in addition the our Combat Meth
Act, it will put the office of the national director, who is supposed
to be in charge of narcotics, in a position of having an organized
effort now on methamphetamine, which has been in every State an
increasing major threat to so many families. It has sections on drug-
endangered children and others.
Approximately 75 to 90 percent of all crime in America is related or
at least enabled by drug and alcohol abuse; that in many States where
we had hearings as many as 80 percent of the kids in child custody
protection were because of meth or other drug abuse and danger to
children. We heard horror stories about people high on narcotics who
even put their baby children in a stove or others to warm them up
because they were so wiped out. The Dawson family in Baltimore who were
fire-bombed because they were afraid they were going to be witnesses in
a case.
This bill addresses most of those things. It is absolutely essential
that we get this department reauthorized with some guidelines because,
unless Congress does its work, there are no guidelines on the executive
branch to try to respond to what we are hearing in our grass roots.
So, once again, I want to thank Mr. Cummings, Mr. Davis, Mr. Waxman
and those in the Senate who have worked so long and hard on this, and I
urge all Members to pass it.
Madam Speaker, I reserve my time.
Mr. CUMMINGS. Madam Speaker, I yield 5 minutes to the distinguished
gentleman from Illinois (Mr. Davis), a member of our subcommittee who
has worked tirelessly on this issue and has just been a real champion.
Mr. DAVIS of Illinois. Madam Speaker, first of all, I want to thank
the gentleman from Maryland for yielding.
I also want to commend Chairman Souder and Ranking Member Cummings
for the tenacious and outstanding work that they have done on this
issue ever since I have been associated with them and affiliated with
the subcommittee. As a matter of fact, they have traveled all over
America, the length and breadth of the country, listening to people,
visiting with people. As a matter of fact, I do not know anybody who
has worked harder on an issue than they have, and so I commend both of
you for your tenacity and outstanding work.
I rise in support of H.R. 2829, Drug Control Policy Reauthorization
Act of 2005, a policy which addresses prevention, interdiction and
treatment, as well as all aspects of law enforcement.
The use and abuse of illegal, illicit and contraband drugs is one of
the most challenging and difficult problems facing America. For
example, in Cook County where I live, in a survey that was taken a
couple of years ago, 800,000 individuals indicated that they used
drugs, 800,000. I grant you that we have a population of over 5 million
people but 800,000 of those said that they used illicit drugs; 300,000
indicated that they were what we call hard core drug users, every day
or whenever they could find the money to purchase what
[[Page H8966]]
they need. As a matter of fact, the Chicago police records suggest that
75 percent of all the people that they arrest test positive for drug
use.
If we could somehow or another reduce the use of drugs, crime
statistics would go so far down until sometimes we would have a hard
time finding them. There is a direct correlation between crime and drug
use in America.
As a result of looking at this problem, I have become more and more a
fan of what I call treatment on demand; that is, enough resources so
that when individuals who are addicted decide that they are ready for
treatment, that treatment is available to them and so that they do not
have to wait 90 days or 60 days to get into a program, because in 90
days or 60 days or 30 days they may have decided that they do not want
treatment anymore. So we lose the opportunity.
While again I commend Chairman Souder, Ranking Member Cummings and
certainly Chairman Tom Davis and Ranking Member Henry Waxman for all of
the attention that they have given, I hope that as we go into the new
Congress in January that we can build upon the outstanding work that
this subcommittee and the Committee on Government Reform has done and
make certain that we have not only the resources available for law
enforcement for prevention but that we also have enough resources
available for treatment.
{time} 1615
Mr. SOUDER. Madam Speaker, I reserve the balance of my time.
Mr. CUMMINGS. Madam Speaker, may I inquire as to how much time we
have.
The SPEAKER pro tempore. The gentleman from Maryland has 6 minutes
remaining.
Mr. SOUDER. Has the gentleman closed on the other side?
The SPEAKER pro tempore. And the gentleman from Indiana has 10
minutes remaining.
Mr. CUMMINGS. I just want to say this, Madam Speaker. One of the
things that we were concerned about was our HIDTA programs, High
Intensity Drug Trafficking Areas. When we saw the budget, the budget
basically cut substantially the funds for HIDTA, and we in our
subcommittee and in our committee have seen the great work of the HIDTA
throughout our country and we were determined to make sure that they
stayed intact and continued to do the jobs that they have done so
effectively.
One of the good things about HIDTA is that they are able to bring
together our Federal, our local, and our State law enforcement officers
so they can work together. And, again, going back to our taxpayers' tax
dollars, to use those dollars effectively and efficiently to fight drug
violence and drug crimes, crimes related to drugs.
But as I sat and listened to Congressman Davis and certainly to Mr.
Souder, I could not help but be reminded of just about 4 months ago as
I was standing in my district in a supermarket and a young man standing
in front of me was talking to me saying he was looking for a job, and
he pulled up his shirt and he showed me the barrel of a gun. And as he
was standing there, he said, I am looking for a job because I simply do
not want to continue to go around sticking up people to feed my drug
habit.
That thing really shook me up, because when you have got somebody
possibly committing two or three robberies a day, as he told me, that
says a lot. And I think that we fail sometimes to understand how deep
this problem is and how it goes against the very safety of all of our
residents, no matter where they may live. And if there is anything that
I have learned from being on this subcommittee, it is that there are no
boundaries. There really are no boundaries with regard to drug
addiction and the problem of drugs. One of the things that I know Mr.
Souder will agree with me, when we got so much interest from our
friends in the Congress who are seeing just a terrible problem with
methamphetamines, they have come forth and they have been very, very
helpful in helping us to figure out how to address not only the
problems of methamphetamines, but the problems associated with heroin,
associated with crack cocaine, with cocaine, and so many other drugs.
So I think that all of us have to understand that, no matter where we
may live or who we may represent, that we all may have different
problems but still we need to work together to address those problems
in a way that is effective for all of us, because, again, we are trying
to heal the Nation and heal those people who have again found
themselves in the clutches of this horrible, horrible situation.
Madam Speaker, I yield back the balance of my time.
Mr. SOUDER. I urge all Members to support the passage of H.R. 6344,
as amended, and I yield back the balance of my time.
The SPEAKER pro tempore. The question is on the motion offered by the
gentleman from Indiana (Mr. Souder) that the House suspend the rules
and pass the bill, H.R. 6344, as amended.
The question was taken; and (two-thirds of those voting having
responded in the affirmative) the rules were suspended and the bill, as
amended, was passed.
A motion to reconsider was laid on the table.
____________________